Delivery of DNA binding and transcriptional regulation compositions
Engineered DNA-binding dimers with modified bZIP proteins, formulated in nanoparticles, address the challenges of targeting oncogenic transcription factors by enhancing stability and binding affinity, effectively suppressing tumor growth and oncogenic pathways in cancer therapy.
Patent Information
- Application Number
- PCT/US2024/030888
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current therapies for targeting oncogenic transcription factors like XBP1 and HIF1α are hindered by challenges in specificity, stability, and delivery, particularly in cancer treatment, where these factors are overexpressed and contribute to tumor growth and resistance.
Development of engineered DNA-binding dimers with modified bZIP proteins, incorporating specific amino acid substitutions and linkages, formulated in nanoparticle compositions to enhance stability and binding affinity, allowing for targeted regulation of gene expression and tumor suppression.
The engineered DNA-binding dimers effectively compete with XBP1 and HIF1α for DNA binding, suppressing oncogenic pathways and inhibiting tumor growth, offering a novel approach to cancer therapy by directly targeting these transcription factors.
Smart Images

Figure US2024030888_28112024_PF_FP_ABST
Abstract
Description
DESCRIPTIONDELIVERY OF DNA BINDING AND TRANSCRIPTIONAL REGULATION COMPOSITIONSCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 468,432, filed May 23, 2023, which is hereby incorporated by reference in its entirety.SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which has been submitted in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 22, 2024, is named “ARCD.P0806WO - Sequence Listing.xml” and is 149,277 kilobytes in size.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0003] This invention was made with government support under DP2GM 128199-01 and 1R01CA223184 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUNDI. Field of the Invention
[0004] Aspects of this invention relate at least to the fields of synthetic chemistry, structural biology, and molecular biology. In some particular aspects, the invention can include nanoparticle compositions comprising engineered DNA-binding dimers that include at least first and second bZIP proteins having specific modifications that the increase stability of the dimers and / or increase binding affinity of the dimers to target DNA sequences.II. Background
[0005] Basic leucine zipper (bZIP)-containing transcription factors (zTFs) are powerful proteins that turn specific genes “on” or “off’ by binding to nearby DNA. By controlling gene expression, zTFs have a major influence on cell behavior, such as whether cells grow or die, and as such are overexpressed or deregulated in the majority of cancers. Despite the profound need for- 1 -SUBSTITUTE SHEET (RULE 26)targeted therapies against zTFs, they remain largely untapped as drug targets due to the challenges of targeting protein-DNA interactions.
[0006] Transcription factors (TFs) control gene expression and cellular state by binding and recruiting regulatory complexes to specific DNA promoter and enhancer sequences in the genome. Dysregulation of TF activity is causal in the initiation and progression of cancer and many other diseases1,2. Despite their biological validation as some of the most direct and effective targets for cancer treatment3, the majority of TFs remain untapped as drug targets due to the challenges of targeting protein-protein and protein-DNA interactions. Moreover, targeting one TF alone may be insufficient to turn off a disease-associated transcriptional program, owing to overlapping regulation of genes by several TFs.
[0007] Two archetypal, and as-yet untargeted oncogenic TFs are X-box binding protein 1 (XBP1) and hypoxia-inducible factor la (HIFla). Both XBP1 and HIFla are activated in cancer cells by changes in nutrient availability, hyperactive metabolism and hypoxia in the tumor microenvironment, which causes them to form complexes at canonical DNA motifs, such as the unfolded protein response element (UPRE)4and hypoxia-induced response element (HRE),5’6respectively. These operator motifs exist upstream of an array of target genes that promote tumor cell survival, proliferation and therapeutic resistance. HIFla is widely implicated in driving malignant phenotypes, including drug resistance and metastasis, in essentially all solid tumors7'9. Likewise, the spliced, active form of XBP1 (referred to as XBPls) is mutated, overexpressed or activated in numerous solid and blood cancers10'12. Intriguingly, an increasing body of evidence suggests that XBP1 and HIFla, which belong to distinct basic leucine zipper (bZIP) and basic helix-loop-helix (bHLH) TF families and have not been shown to directly interact with one another14, may bind and coregulate a subset of hypoxia-responsive genes15. This signature is particularly prevalent in triple negative breast cancer (TNBC), where XBP1 and HIFla are strongly upregulated, correlate with poor patient outcomes, and are required for tumor cell growth and survival in preclinical models of this cancer7’16’17. In principle, TF mimetics that can bind UPRE and / or HRE DNA sequences inside of cells could prevent the recruitment of XBP1 and HIFla to target genes and subsequent activation of oncogenic pathways and phenotypes.
[0008] Despite intense research in these molecules, polyamides have shown poor specificity and pharmacology in animals, and existing protein-mimetics generally suffer from poor stability, cell penetration and pharmacologic properties. Therefore, new technology platforms capable of directly targeting oncogenic TF function, as well as approaches enabling their selective delivery to tumors would represent a major advance in the potential to target tumor growth, sensitivity to immunotherapies and resistance to conventional therapies for many human cancers.- 2 -SUBSTITUTE SHEET (RULE 26)
[0009] There exists a need for delivery compositions comprising specific, high affinity transcription factor mimetics capable of competing for zTF binding to DNA, as well as methods for use of such compositions in research and therapeutic applications.SUMMARY
[0010] The present disclosure addresses certain needs by providing high affinity DNA-binding molecules capable of competing for zTF (e.g., Fos / Jun, XBP1, ATF4, CEBPP, etc.) binding and of reducing expression of zTF target genes formulated in nanoparticle compositions. In one aspect of the present invention, the inventors have discovered that certain modifications can be made to bZIP dimers that allow for increased efficacy and / or stability of the dimers. Non-limiting examples of such modifications can include (1) the use of intrapeptide stabilizing linkages in the bZIP dimers, (2) linkages between first and second bZIP proteins, and / or (3) certain amino acid substitutions made to the first and / or second bZIP proteins. An example of such a modification can include amino acid substitutions made to the leucine zipper domain sequences of the first and second bZIP proteins that form engineered dimers of the present invention. In one example, such amino acid substitutions can include, any one of, any combination of, or all of the following substitutions: (i) each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “a” of their respective leucine zipper domain sequences; (ii) each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “d” of their respective leucine zipper domain sequences; (iii) each of the first and second bZIP proteins, individually, have a leucine at position “a” of their respective leucine zipper domain sequences; (iv) each of the first and second bZIP proteins, individually, have an isoleucine at position “a” of their respective leucine zipper domain sequences; each of the first and second bZIP proteins, individually, have a leucine at position “d” of their respective leucine zipper domain sequences; (v) each of the first and second bZIP proteins, individually, have an isoleucine at position “d” of their respective leucine zipper domain sequences; (vi) a glutamine is present at position “e” of the leucine zipper domain sequence of the first bZIP protein and a glutamine is present at position “g” of the leucine zipper domain sequence of the second bZIP protein, or an arginine is present at position “e” of the leucine zipper domain sequence of the first bZIP protein and a glutamic acid is present at position “g” of the leucine zipper domain sequence of the second bZIP protein; (vii) an arginine is present at position “e” of the leucine zipper domain sequence of the second bZIP protein and a glutamic acid is present at position “g” of the leucine zipper domain sequence of the first bZIP protein; and / or (viii) at least one or both of the leucine zipper domain sequences of the first and / or second bZIP proteins have an alanine at least at one or more of positions “b”, “c”, or “f”. With out wishing to be bound by theory, and as illustrated in non-- 3 -SUBSTITUTE SHEET (RULE 26)limiting embodiments in the Examples, modifications (1), (2), and / or (3) are believed to increase the stability of the DNA-binding dimers of the present invention and / or increase the binding affinity of the DNA-binding dimers of the present invention to target DNA sequences. Increased stability and / or increased binding affinity can result in more effective dimers for therapeutic uses.
[0011] Also disclosed are methods for design and synthesis of such high affinity DNA-binding molecules starting from any natural zTF as a template. Engineered peptides useful as, for example, precursors in synthesis of DNA-binding molecules are also described herein. Further disclosed are methods for use of the disclosed DNA-binding molecules in various applications, including modifying gene expression and treatment of various conditions (e.g., cancer, fibrosis, diabetes). Certain aspects are directed to use of the disclosed DNA-binding molecules for targeting XBP1 and / or HIFla for treatment of cancer such as triple negative breast cancer (TNBC).
[0012] The inventors also discovered that the engineered proteins can be formulated in nanoparticle compositions to improve pharmacodynamics, pharmacokinetics, efficacy, tolerability, and other pharmaceutical properties of the engineered proteins.
[0013] Aspects of the present disclosure include nanoparticle compositions comprising engineered DNA-binding dimers, bZIP transcriptional repressors, bHLH transcriptional repressors, engineered peptides, pharmaceutical compositions, methods for designing engineered peptides, methods for synthesizing engineered peptides, methods for designing engineered DNA- binding dimers, methods for synthesizing engineered DNA-binding dimers, methods for introducing engineered DNA-binding dimers into a cell, methods for altering gene expression, methods for designing nanoparticle compositions, methods for administering nanoparticle compositions. Engineered DNA-binding dimers of the disclosure can include at least 1, 2, 3, 4, or more of the following: an engineered peptide, an interpeptide linker, a modified basic domain sequence, a modified leucine zipper domain sequence, a non-natural amino acid, an intramolecular helix stabilizing linker, and a intrapeptide stabilizing linkage. Any one or more of the preceding components may be excluded in certain aspects. Methods of the present disclosure can include at least 1, 2, 3, 4, 5, or more of the following steps: obtaining a sequence of abZIP protein, identifying a basic domain of a bZIP protein, identifying a leucine zipper domain of a bZIP protein, obtaining a sequence of a bHLH protein, identifying a basic domain of a bHLH protein, identifying a leucine zipper domain of a bHLH protein, designing an engineered peptide, synthesizing an engineered peptide, synthesizing an engineered DNA-binding dimer, introducing an engineered DNA-binding dimer into a cell, culturing a cell with an engineered DNA-binding dimer, administering a composition comprising an engineered DNA-binding dimer to a subject, administering nanoparticle compositions to a subject, protecting engineered proteins using a nanoparticle, and- 4 -SUBSTITUTE SHEET (RULE 26)generating a nanoparticle composition. Any one or more of the preceding steps may be excluded in aspects of the disclosure.
[0014] Disclosed herein, in some aspects, are nanoparticle compositions comprising a nanoparticle and an engineered DNA-binding dimer. In certain aspects, the engineered DNA- binding dimer comprises (a) a first engineered peptide comprising (i) a basic domain sequence of a first bZIP protein and (ii) a leucine zipper domain sequence of the first bZIP protein; and (b) a second engineered peptide linked to the first engineered peptide via a side-by-side interpeptide linkage, the second engineered peptide comprising (i) a basic domain sequence of a second bZIP protein and (ii) a leucine zipper domain sequence of the second bZIP protein. In some aspects, the engineered peptides can be modified by: (1) introducing intrapeptide stabilizing linkages in the first and / or second bZIP proteins (e.g., linkages can be included in the basic domain and / or the leucine zipper domain sequences, preferably the basic domain sequences, of the first and / or second bZIP proteins; (2) introducing specific linker molecules to link together (e.g., covalent bond) the first and second bZIP proteins and / or where the linker molecules link together the first and second bZIP proteins; and / or (3) introducing amino acid substitutions into the first and / or second bZIP proteins. In one aspects, the engineered DNA-binder dimers of the present invention can be modified such that each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “a” of their respective leucine zipper domain sequences, and / or each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “d” of their respective leucine zipper domain sequences. In some aspects, the engineered DNA- binding dimer can have a modification such that each of the first and second bZIP proteins, individually, have a leucine at position “a” of their respective leucine zipper domain sequences. In other aspects, the engineered DNA-binding dimer can have a modification such that each of the first and second bZIP proteins, individually, have an isoleucine at position “a” of their respective leucine zipper domain sequences. In some aspects, each of the first and second bZIP proteins, individually, have a leucine at position “d” of their respective leucine zipper domain sequences. In other aspects, each of the first and second bZIP proteins, individually, have an isoleucine at position “d” of their respective leucine zipper domain sequences. In yet another aspect, the engineered DNA-binding dimers of the present invention can include a glutamine at position “e” of the leucine zipper domain sequence of the first bZIP protein and a glutamine at position “g” of the leucine zipper domain sequence of the second bZIP protein or an arginine at position “e” of the leucine zipper domain sequence of the first bZIP protein and a glutamic acid at position “g” of the leucine zipper domain sequence of the second bZIP protein. In yet another aspects, the engineered DNA-binding dimers of the present invention can include an arginine at position “e” of the leucine zipper domain sequence of the second bZIP protein and a glutamic acid at position- 5 -SUBSTITUTE SHEET (RULE 26)“g” of the leucine zipper domain sequence of the first bZIP protein. In some aspects, the engineered DNA-binding dimers of the present invention can be mnodified such that at least one or both of the leucine zipper domain sequences of the first and / or second bZIP proteins have an alanine at least at one or more of positions “b”, “c”, or “f”.
[0015] In some aspects, the modified basic domain sequence of the first bZIP protein is at most, at least, or exactly 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 residues in length. In some aspects, the modified basic domain sequence of the first bZIP protein is at most 25 residues in length. In some aspects, the modified basic domain sequence of the first bZIP protein is 20 residues in length. The modified basic domain sequence may have at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity with the basic domain of the first bZIP protein. The modified basic domain sequence may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 residues from the basic domain of the first bZIP protein. In some aspects, the modified leucine zipper domain sequence of the first bZIP protein is at most, at least, or exactly 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, or 8 residues in length. In some aspects, the modified leucine zipper domain sequence of the first bZIP protein is at most 15 residues in length. In some aspects, the modified leucine zipper domain sequence of the first bZIP protein is 12 residues in length. The modified leucine zipper binding domain sequence may have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity with the leucine zipper domain of the first bZIP protein. The modified leucine zipper domain sequence may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 residues from the leucine zipper domain of the first bZIP protein.
[0016] In some aspects, the modified basic domain sequence of the second bZIP protein is at most, at least, or exactly 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, or 15 residues in length. In some aspects, the modified basic domain sequence of the second bZIP protein is at most 25 residues in length. In some aspects, the modified basic domain sequence of the second bZIP protein is 20 residues in length. The modified basic domain sequence may have at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity with the basic domain of the second bZIP protein. The modified basic domain sequence may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 residues from the basic domain of the second bZIP protein. In some aspects, the modified leucine zipper domain sequence of the second bZIP protein is at most, at least, or exactly 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, or 8 residues in length. In some aspects, the modified leucine zipper domain sequence of the second bZIP protein is at most 15 residues in length. In some aspects, the modified leucine zipper domain sequence of the second bZIP protein is 12 residues in length. The modified leucine zipper binding domain sequence may have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%- 6 -SUBSTITUTE SHEET (RULE 26)identity with the leucine zipper domain of the second bZIP protein. The modified leucine zipper domain sequence may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 residues from the leucine zipper domain of the second bZIP protein.
[0017] In some aspects, the first engineered peptide is at most 40 residues in length. In some aspects, the first engineered peptide is 32 residues in length. In some aspects, the second engineered peptide is at most 40 residues in length. In some aspects, the second engineered peptide is 32 residues in length. In some aspects, the modified basic domain sequence of the first bZIP protein comprises a serine substituted for any cysteine relative to a native basic domain sequence of the first bZIP protein. In some aspects, the modified basic domain sequence of the second bZIP protein comprises a serine substituted for any cysteine relative to a native basic domain sequence of the second bZIP protein. In some aspects, the modified leucine zipper domain sequence of the first bZIP protein comprises an alanine substituted for any cysteine at a “b”, “c”, or “f” position relative to a native leucine zipper domain sequence of the first bZIP protein, the modified leucine zipper domain sequence of the first bZIP protein comprises a leucine substituted for any cysteine at an “a” or “d” position relative to a native leucine zipper domain sequence of the first bZIP protein. In some aspects, the modified leucine zipper domain sequence of the second bZIP protein comprises an alanine substituted for any cysteine at a “b”, “c”, or “f ’ position relative to a native leucine zipper domain sequence of the second bZIP protein. In some aspects, the modified leucine zipper domain sequence of the second bZIP protein comprises a leucine substituted for any cysteine at an “a” or “d” position relative to a native leucine zipper domain sequence of the second bZIP protein.
[0018] In some aspects, the modified basic domain sequence of the first bZIP protein comprises a cysteine at a position corresponding to the last position of a native basic domain sequence of the first bZIP protein. In some aspects, the modified leucine zipper domain sequence of the second bZIP protein comprises a lysine at a position corresponding to a first “e” position of a native leucine zipper domain sequence of the second bZIP protein. In some aspects, the interpeptide linkage is between the cysteine and the lysine. In some aspects, the modified leucine zipper domain sequence of the first bZIP protein comprises a leucine in place of any residue at an “a” or “d” position that is not a leucine or isoleucine relative to a native leucine zipper domain of the first bZIP protein. In some aspects, the modified leucine zipper domain sequence of the second bZIP protein comprises a leucine in place of any residue at an “a” or “d” position that is not a leucine or isoleucine relative to a native leucine zipper domain of the second bZIP protein.
[0019] In some aspects, the first bZIP protein is c-Fos. In some aspects, the modified DNA- binding domain sequence of c-Fos comprises: IRRERNKMAAAKSRNRRREC (SEQ ID NO: 16); IRR#RNK#AAAKSRNRRREC (SEQ ID NO: 17); EEKRRIRRERNKMAAAKSRNRRREC- 7 -SUBSTITUTE SHEET (RULE 26)(SEQ ID NO: 18); or EEKRRIRR#RNK#AAAKSRNRRREC (SEQ ID NO: 19); wherein # are intrapeptide stabilizing linkage sites which together form the structuresome aspects, the modified leucine zipper domain sequence of c-Fos comprises: TDTLEDETDQLE (SEQ ID NO20); LDELQAEIEQLE (SEQ ID NO:21); IDELQAEIEQLE (SEQ ID NO:22); IDEIQAEIEQIE (SEQ ID NO:23); L#ELQ#EIEQLE (SEQ ID NO:24);I#ELQ#EIEQLE (SEQ ID NO:25); or I#EIQ#EIEQIE (SEQ ID NO:26); wherein # are intrapeptide stabilizing linkage sites, which together form the structure
[0020] In some aspects, the second bZIP protein is c-Jun. In some aspects, the modified DNA- binding domain sequence of c-Jun is: RKRMRNRIAASKSRKRKLER (SEQ ID NO:27); RKR#RNR#AASKSRKRKLER (SEQ ID NO:28); RIKAERKRMRNRIAASKSRKRKLER(SEQ ID NO:29); or RIKAERKR#RNR#AASKSRKRKLER (SEQ ID NO:30); wherein # are intrapeptide stabilizing linkage sites, which together form the structureIn some aspects, the modified leucine zipper domain sequence of c-Jun comprises: lAKmLEEKVKTLK (SEQ ID NO:31); lARLKmEKVKTLK (SEQ ID NO:32);AAELKmEKVATLK (SEQ ID NO:33); lARLKmEKIKTLK (SEQ ID NO:34); lARIKmEKIKTIK (SEQ ID NO: 35); I#RLKm#KVKTLK (SEQ ID NO: 36); orI#RLKm#KIKTLK (SEQ ID NO: 37); wherein # are intrapeptide stabilizing linkage sites, which together form the structureLys residue attached to a maleimide-linker forming a portion of the structure:SUBSTITUTE SHEET (RULE 26)
[0021] In some aspects, the first bZIP protein is XBP1. In some aspects, the modified DNA- binding domain sequence of XBP1 comprises: RRKLKNRVAAQTARDRKKAC (SEQ ID NO: 38); or RRK#KNR#AAQTARDRKKAC (SEQ ID NO: 39); wherein # are intrapeptide stabilizing linkage sites, which together form the structure. In some aspects, the modified leucine zipper domain sequence of XBP1 comprises: MSELEQQVVDLE(SEQ ID NO:40); LSELEQQVVDLE (SEQ ID NO:41); or L#ELE#QVVDLE (SEQ ID NO:42); wherein # are intrapeptide stabilizing linkage sites, which together form the structure
[0022] In some aspects, the second bZIP protein is XBP1. In some aspects, the modified DNA- binding domain sequence of XBP1 comprises: RRKLKNRVAAQTARDRKKAR (SEQ ID NO:43); or RRK#KNR#AAQTARDRKKAR (SEQ ID NO:44); wherein # are intrapeptide stabilizing linkage sites, which together form the structure. In some aspects, the modified leucine zipper domain sequence of XBP1 comprises: MSELKmQQVVDLE(SEQ ID NO:45); LSELKmQQVVDLE (SEQ ID NO:46); or L#ELKm#QVVDLE (SEQ IDNO:47); wherein # are intrapeptide stabilizing linkage sites, which together form the structureLys residue attached to a maleimide-linker forming a portion- 9 -SUBSTITUTE SHEET (RULE 26)
[0023] In some aspects, the first bZIP protein is ATF4. In some aspects, the modified DNA- binding domain sequence of ATF4 comprises: KKMEQNKTAATRYRQKKRAC (SEQ IDNO:48); wherein # are intrapeptide stabilizing linkage sites, which together form the structuresome aspects, the modified leucine zipper domain sequence of ATF4 comprises: QEALTGELKELE (SEQ ID NO:49); LEALKAELKELR (SEQ ID NO:50); or L#ALK#ELKELR (SEQ ID NO:51).
[0024] In some aspects, the first bZIP protein is CZEBPp. In some aspects, the modified DNA- binding domain sequence of CZEBPP comprises IRRERNNIAVRKSRDKAKMC (SEQ IDNO: 52); wherein # are intrapeptide stabilizing linkage sites, which together form the structureIn some aspects, the modified leucine zipper domain sequence ofC / EBPP comprises: LLELQHKVLELR (SEQ ID NO:53); or L#ELQ#KVLELR (SEQ ID NO:54); wherein # are intrapeptide stabilizing linkage sites, which together form the structure
[0025] In some aspects, the second bZIP protein is ATF4. In some aspects, the modified DNA- binding domain sequence of ATF4 comprises KKMEQNKTAATRYRQKKRAE (SEQ ID NO: 55); wherein # are intrapeptide stabilizing linkage sites, which together form the structure- 10 -SUBSTITUTE SHEET (RULE 26)some aspects, the modified leucine zipper domain sequence of ATF4 comprises: QEALKmGELKELE (SEQ ID NO:56); LEALKmAELKELR (SEQ ID NO:57); orL#ALKm#ELKELR (SEQ ID NO: 58); wherein # are intrapeptide stabilizing linkage sites, which
[0026] In some aspects, the first engineered peptide comprises a intrapeptide stabilizing linkage. In some aspects, the second engineered peptide comprises a intrapeptide stabilizing linkage. In some aspects, the intrapeptide stabilizing linkage is between the fourth position and the eighth position of the first engineered peptide. In some aspects, the intrapeptide stabilizing linkage is between the twenty-second position and the twenty-sixth position of the first engineered peptide.In some aspects, the interpeptide linkage comprises a maleimide-thiol adduct. In some aspects, the interpeptide linkage i
[0027] Disclosed herein, in certain aspects, is an engineered DNA-binding dimer having one of the following formulas:SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)
[0028] Further disclosed is an engineered DNA-binding dimer having a formula or structure depicted in any one of FIGs. 9-86.
[0029] The nanoparticle of the nanoparticle composition can be any nanoparticle capable of encapsulating a protein composition. In some aspects, the nanoparticle comprises nanoscale coordination polymers. The nanoscale coordination polymers include nanoparticles that selfassemble. The nanoscale coordination polymers can comprise metals and metalloligands for selfassembly. In some aspects, the l,2-dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-dioleoyl-sn- glycero-3 -phosphocholine (DOPC), l,2-diastearoyl-sn-glycero-3-phosphoethanolamine-N- [amino(polyethylene glycol)2000] (DSPE-PEG2000), zinc, and / or cholesterol. The nanoparticle can comprise an outer layer and an inner layer. The nanoparticle can comprise a core-shell composition. The therapeutic agent, which may be any engineered protein disclosed herein, can be incorporated into the core or shell or be between the outer layer and inner layer. The nanoparticle can comprises an oil-in-water emulsion, water-in-oil emulsion, water-in-oil-in-water emulsion, oil-in-water-in-oil emulsion, liposome, solid lipid particles formulation, or combination thereof. Also disclosed are nanoparticles comprising solid lipid nanoparticles, liposomes (and variants including multi-lamellar, double liposome preparations, etc.), niosomes, ethosomes, electrostatic particulates, microemulsions, nanoemulsions, microsuspensions, nanosuspensions, or combinations thereof. It is also contemplated that the nanoparticles do not comprise solid lipid nanoparticles, liposomes (and variants including multi-lamellar, double liposome preparations, etc.), niosomes, ethosomes, electrostatic particulates, microemulsions, nanoemulsions, microsuspensions, nanosuspensions, or combinations thereof. Also disclosed are nanoparticles comprising multilamellar nanoparticle vesicles, unilamellar nanoparticle vesicles, multivesicular nanoparticles, emulsion particles, irregular particles with lamellar structures and bridges, partial emulsion particles, combined lamellar and emulsion particles, or combinations thereof. It is also contemplated that the nanoparticles do not comprise multilamellar nanoparticle vesicles, unilamellar nanoparticle vesicles, multivesicular nanoparticles, emulsion particles, irregular particles with lamellar structures and bridges, partial emulsion particles, combined lamellar and emulsion particles, or combinations thereof.
[0030] Also disclosed, in some aspects, is a method for modifying expression of a gene in a cell, the method comprising providing to the cell an engineered DNA-binding dimer of the present disclosure formulated in a nanoparticle composition. Further disclosed, in some aspects, is a method for treating a subject for a condition, the method comprising administering to the subject an effective amount of an engineered DNA-binding dimer of the present disclosure formulated in a nanoparticle composition.- 27 -SUBSTITUTE SHEET (RULE 26)
[0031] In some aspects, the condition is fibrosis. In some aspects, the fibrosis is liver fibrosis, renal fibrosis, cardiac fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), scleroderma, psoriasis, or myelofibrosis. In some aspects, the condition is diabetes. In some aspects, the condition is type 1 diabetes. In some aspects, the condition is type 2 diabetes. In some aspects, the condition is cancer. In some aspects, the cancer is leukemia, lymphoma, myeloma, triple negative breast cancer, prostate cancer, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, ovarian cancer, lung adenocarcinoma, liver cancer, glioblastoma, or renal cell carcinoma. In some aspects, the cancer is breast cancer. In some aspects, the breast cancer is triple negative breast cancer. In some aspects, the method further comprises administering to the subject an additional cancer therapy. In some aspects, the additional cancer therapy is chemotherapy, radiotherapy, immunotherapy, or a proteasome inhibitor. In some aspects, the subject was previously treated with a cancer therapy. In some aspects, the subject was determined to be resistant to the cancer therapy. In some aspects, the cancer therapy is chemotherapy, radiotherapy, or immunotherapy.
[0032] Disclosed herein, in some aspects, is an engineered peptide having the sequence: Ac- IRRERNKMAAAKSRNRRRECTDTLEDETDQLE-NH2 (SEQ ID NO:59), Ac- IRRERNKMAAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO: 60), Ac- IRRERNKMAAAKSRNRRRECIDELQAEIEQLE-NH2 (SEQ ID NO:61), Ac- IRRERNKMAAAKSRNRRRECIDEIQAEIEQIE-NH2 (SEQ ID NO: 62), Ac- IRR#RNK#AAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO:63), Ac- IRRERNKMAAAKSRNRRRECL#ELQ#EIEQLE-NH2 (SEQ ID NO: 64), Ac- IRR#RNK#AAAKSRNRRRECIDELQAEIEQLE-NH2 (SEQ ID NO:65), Ac- IRRERNKMAAAKSRNRRRECI#ELQ#EIEQLE-NH2 (SEQ ID NO: 66), Ac- IRR#RNK#AAAKSRNRRRECIDEIQAEIEQIE-NH2 (SEQ ID NO: 67), Ac- IRRERNKMAAAKSRNRRRECI#EIQ#EIEQIE-NH2 (SEQ ID NO:68), Ac-EEKRRIRRERNKMAAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO: 69), Ac- EEKRRIRR#RNK#AAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO: 70), or ACEEKRRIRRERNKMAAAKSRNRRRECL#ELQ#EIEQLE-NH2 (SEQ ID NO:71), wherein Ac is acetyl; and # is (S)-2-(4’-pentenyl)alanine. In some aspects, the engineered peptide has the sequence Ac-IRRERNKMAAAKSRNRRRECI#EIQ#EIEQIE-NH2 (SEQ ID NO: 68).
[0033] Disclosed herein, in some aspects, is an engineered peptide having the sequence: Ac- RKRMRNRIAASKSRKRKLERIAKmLEEKVKTLK-NH2 (SEQ ID NO: 72), Ac-RKRMRNRIAASKSRKRKLERIARLKmEKVKTLK-NH2 (SEQ ID NO:73), Ac-RKRMRNRIAASKSRKRKLERAAELKmEKVATLK-NH2 (SEQ ID NO: 74), Ac-RKRMRNRIAASKSRKRKLERIARLKmEKIKTLK-NH2 (SEQ ID NO:75), Ac-- 28 -SUBSTITUTE SHEET (RULE 26)RKRMRNRIAASKSRKRKLERIARIKmEKIKTIK-NH2 (SEQ ID NO: 76), AC¬RKR#RNR#AASKSRKRKLERIARLKmEKVKTLK-NH2 (SEQ ID NO: 77), AC¬RKRMRNRIAASKSRKRKLERI#RLKm#KVKTLK-NH2 (SEQ ID NO:78), AC¬RKR#RNR#AASKSRKRKLERIARLKmEKIKTLK-NH2 (SEQ ID NO: 79), AC¬RKRMRNRIAASKSRKRKLERI#RLKm#KIKTLK-NH2 (SEQ ID NO: 80), AC¬RI KAERK RM RN RIA A SI<SRI<RI< LERI A RLKm EK VKTLK-NH2 (SEQ ID NO: 81), Ac-RI KAERKR#RNR# A A SI<SRI<RI< LERI A RLKm EK VKTLK-NH2 (SEQ ID NO: 82), or Ac-RIKAERKRMRNRIAASKSRKRKLERI#RLKm#KVKTLK-NH2 (SEQ ID NO:83), wherein Ac is acetyl; # is (S)-2-(4’-pentenyl)alanine; and Km is Lys(Mmt) or a Lys residue linked to a maleimide linker. In some aspects, the engineered peptide has the sequence Ac- RKRMRNRIAASKSRKRKLERI#RLKm#KIKTLK-NH2 (SEQ ID NO:80).
[0034] Disclosed herein, in some aspects, is an engineered peptide having the sequence: Ac- RRKLKNRVAAQTARDRKKACMSELEQQVVDLE-NH2 (SEQ ID NO: 84), Ac- RRKLKNRVAAQTARDRKKACLSELEQQVVDLE-NH2 (SEQ ID NO:85), Ac- RRKLKNRVAAQTARDRKKACL#ELE#QVVDLE-NH2 (SEQ ID NO: 86), or Ac- RRK#KNR#AAQTARDRKKACLSELEQQVVDLE-NH2 (SEQ ID NO:87), wherein Ac is acetyl; and # is (S)-2-(4’-pentenyl)alanine. In some aspects, the engineered peptide has the sequence Ac-RRK#KNR#AAQTARDRKKACLSELEQQVVDLE-NH2(SEQ ID NO:87).
[0035] Disclosed herein, in some aspects, is an engineered peptide having the sequence: Ac- RRKLKNRVAAQTARDRKKARMSELKmQQVVDLE-NH2 (SEQ ID NO:88), Ac- RRKLKNRVAAQTARDRKKARLSELKmQQVVDLE-NH2 (SEQ ID NO: 89), Ac- RRKLKNRVAAQTARDRKKARL#ELKm#QVVDLE-NH2 (SEQ ID NO: 90), or Ac- RRK#KNR#AAQTARDRKKARLSELKmQQVVDLE-NH2 (SEQ ID NO:91), wherein Ac is acetyl; # is (S)-2-(4’-pentenyl)alanine; and Km is Lys(Mmt) or a Lys residue linked to a maleimide linker. In some aspects, the engineered peptide has the sequence Ac- RRK#KNR#AAQTARDRKKARLSELKmQQVVDLE-NH2 (SEQ ID NO:91).
[0036] Disclosed herein, in some aspects, is an engineered peptide having the sequence: Ac- KKMEQNKTAATRYRQKKRACQEALTGELKELE-NH2 (SEQ ID NO: 92), Ac- KKMEQNKTAATRYRQKKRACLEALKAELKELR-NH2 (SEQ ID NO:93), Ac- KKMEQNKTAATRYRQKKRACL#ALK#ELKELR-NH2 (SEQ ID NO:94), wherein Ac is acetyl; and # is (S)-2-(4’-pentenyl)alanine. In some aspects, the engineered peptide has the sequence Ac-KKMEQNKTAATRYRQKKRACQEALTGELKELE-NEb (SEQ ID NO:92).
[0037] Disclosed herein, in some aspects, is an engineered peptide having the sequence: Ac- KKMEQNKTAATRYRQKKRAEQEALKmGELKELE-NH2 (SEQ ID NO: 95), Ac- KKMEQNKTAATRYRQKKRAELEALKmAELKELR-NH2 (SEQ ID NO: 96), or Ac-- 29 -SUBSTITUTE SHEET (RULE 26)KKMEQNKTAATRYRQKKRAEL#ALKm#ELKELR-NH2 (SEQ ID NO:97), wherein Ac is acetyl; # is (S)-2-(4’-pentenyl)alanine; and Km is Lys(Mmt) or a Lys residue linked to a maleimide linker. In some aspects, the engineered peptide has the sequence Ac- KKMEQNKTAATRYRQKKRAEL#ALKm#ELKELR-NH2 (SEQ ID NO:97).
[0038] Disclosed herein, in some aspects, is an engineered peptide having the sequence: Ac- IRRERNNIAVRKSRDKAKMCLLELQHKVLELR-NH2 (SEQ ID NO: 98), or Ac- IRRERNNIAVRKSRDKAKMCL#ELQ#KVLELR-NH2 (SEQ ID NO:99), wherein Ac is acetyl; and # is (S)-2-(4’-pentenyl)alanine. In some aspects, the engineered peptide has the sequence Ac- IRRERNNIAVRKSRDKAKMCL#ELQ#KVLELR-NH2 (SEQ ID NO:99).
[0039] Also disclosed is a composition comprising any two of the engineered peptides disclosed herein. Further disclosed is a method for generating an engineered DNA-binding dimer, the method comprising subjecting such a composition to conditions sufficient to form a side-by- side interpeptide linkage between the two engineered peptides. The conditions may comprise, for example, providing 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetic acid.
[0040] Further disclosed herein, in some aspects, is a method of reducing expression of a HIF la target gene in a cell, the method comprising providing to the cell a nanoparticle composition comprising an engineered DNA-binding dimer, including any engineered DNA-binding dimer disclosed herein. In some aspects, the engineered DNA-binding dimer comprises a bHLH domain and / or a bZIP domain. In some aspects, the engineered DNA-binding dimer comprises: (a) a first engineered peptide comprising (i) a modified basic domain sequence of XBP1 and (ii) a modified leucine zipper domain sequence of XBP1; and, (b) a second engineered peptide linked to the first engineered peptide via a side-by-side interpeptide linkage, the second engineered peptide comprising (i) a modified basic domain sequence of XBP1 and (ii) a modified leucine zipper domain sequence of XBP1. In some aspects, the engineered DNA-binding dimer is provided in an amount effective to reduce expression of GLUT1 in the cell. In some aspects, the engineered DNA- binding dimer is provided in an amount effective to reduce expression of VEGFA in the cell. In some aspects, the engineered DNA-binding dimer is provided in an amount effective to reduce expression of PGK1 in the cell. In some aspects, the cell is a cancer cell. In some aspects, the cell is a breast cancer cell. In some aspects, the cell is a triple negative breast cancer cell.- 30 -SUBSTITUTE SHEET (RULE 26)
[0041] In some aspects, the engineered DNA-binding dimer has formulaSUBSTITUTE SHEET (RULE 26)In some aspects, the engineered DNA-binding dimer has formulaSUBSTITUTE SHEET (RULE 26)In some aspects, the engineered DNA-binding dimer has formulaSUBSTITUTE SHEET (RULE 26)
[0042] Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the measurement or quantitation method.
[0043] The use of the word “a” or “an” when used in conjunction with the term “comprising” may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
[0044] The phrase “and / or” means “and” or “or”. To illustrate, A, B, and / or C includes: A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C. In other words, “and / or” operates as an inclusive or.
[0045] The words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0046] The compositions and methods for their use can “comprise,” “consist essentially of,” or “consist of’ any of the ingredients or steps disclosed throughout the specification. Compositions and methods “consisting essentially of’ any of the ingredients or steps disclosed limits the scope of the claim to the specified materials or steps which do not materially affect the basic and novel characteristic of the claimed invention.
[0047] “Individual, “subject,” and “patient” are used interchangeably and can refer to a human or non-human.
[0048] Any method in the context of a therapeutic, diagnostic, or physiologic purpose or effect may also be described in “use” claim language such as “Use of’ any compound, composition, or agent discussed herein for achieving or implementing a described therapeutic, diagnostic, or physiologic purpose or effect.
[0049] It is specifically contemplated that any limitation discussed with respect to one aspect of the invention may apply to any other aspect of the invention. Furthermore, any composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or to utilize any composition of the invention. Any aspect discussed with respect to one aspect of the disclosure applies to other aspects of the disclosure as well and vice versa. For example, any step in a method described herein can apply to any other method. Moreover, any method described herein may have an exclusion of any step or combination of steps. Aspects of an aspect set forth in the Examples are also aspects that may be implemented in the context of aspects discussed elsewhere in a different Example or elsewhere in the application, such as in the Summary, Detailed Description, Claims, and Brief Description of the Drawings.- 34 -SUBSTITUTE SHEET (RULE 26)
[0050] It is contemplated that any aspect discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.
[0051] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific aspects of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF THE DRAWINGS
[0052] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific aspects presented herein.
[0053] FIGs. 1-20 shows example synthetic dimers of the present disclosure and DNA binding results measured by electrophoretic mobility shift assay. In some aspects, certain synthetic dimers of FIGs 1-20 are poor binders to DNA and / or do not bind DNA stably, specifically, or at all
[0054] FIG. 21 shows representative characterization of the STR22-NCP nanoparticle compositions.
[0055] FIG. 22 shows LCMS analysis of a serial of different concentration of STR22 in serum.
[0056] FIG. 23 shows administration route, PK, tox profiling with STR-NCP nanoparticle compositions
[0057] FIG. 24 shows IV administered NCP-STR22 accumulation in 4T1 tumors
[0058] FIG. 25 shows a representative pharmacodynamic study with STR22-NCP nanoparticle compositions.
[0059] FIG. 26 shows another representative pharmacodynamic study with STR22-NCP nanoparticle compositions over 24, 48, and 72 hours.
[0060] FIGs. 27A-27B show toxicity studies of STR-NCP nanoparticle compositions in a xenograft model.
[0061] FIGs. 28A-28B show a representative efficacy study with STR22-NCP nanoparticle compositions.
[0062] FIGs. 29A-29D show a representative tolerability study with STR22-NCP nanoparticle compositions.- 35 -SUBSTITUTE SHEET (RULE 26)DETAILED DESCRIPTION OF THE INVENTION
[0063] As described herein, the inventors have developed a modular strategy for generation of synthetic DNA binding molecules capable of competing for DNA binding with bZIP-containing transcription factors (zTFs). These molecules, described herein as “bZIP transcriptional repressors,” “engineered DNA-binding dimers,” or “synthetic transcriptional repressors,” may be generated using the methods and systems described herein using any zTF as a starting point, and thus may be used to compete for binding of any natural zTF. Various example bZIP transcriptional repressors are described herein, along certain examples methods for use, including in DNA binding and modification of gene expression. In some aspects, disclosed are engineered DNA-binding dimers capable of competing for binding with zTFs such as Fos / Jun heterodimers, XBP1 homodimers, ATF4 homodimers, and CEPBP / ATF4 heterodimers.
[0064] The vast majority of oncogenic transcription factors (TFs) are perceived to be undruggable because of the difficulty in targeting extended protein-protein and protein-DNA interaction surfaces. Two of these proteins, XBP1 and HIFla, are stress-responsive TFs that respond to and protect against cellular damage caused by dysregulated metabolism and microenvironmental conditions. Certain aspects herein relate to chemical strategies to create fully synthetic transcriptional repressors (STRs) that mimic one or more bZIP DNA-binding domains, such as those of XBP1. In some aspects, STR22, a synthesized bZIP -binding protein, binds XBP1- and HIF la-target DNA sequences with high potency and specificity and, in some asepcts, directly competes with both TFs at endogenous target gene promoters in cells. In certain aspects, under hypoxic conditions, STR22 globally suppresses HIFla binding to hypoxia response element (HRE) promoters and enhancers and thereby inhibits hypoxia-induced gene expression. In certain aspects, such as in aspects invovling triple negative breast cancer cells, STR22 blocks pro- tumorigenic phenotypes and hypoxia-induced stress protection in cell culture. In some in vivo aspects, where tumor hypoxia is more prevalent, STR22 treatment inhibited HIF la-dependent gene expression and tumor growth. These data from aspects disclosed herein validate a novel strategy for dual targeting of two currently intractable TFs in TNBC and other cancers. Certain aspects also relate to a general strategy to develop antagonists for other bZIP TFs.
[0065] Despite long-standing validation of hypoxia- and HIF la-induced gene expression as a driver of oncogenic phenotypes, the ability to target this axis has remained elusive. Certain aspects present several critical insights into the development of a new class of molecules capable of directly regulating DNA binding by bZIP TFs, as well as their application in targeting XBP1 / HIF la. First, the inventors developed a modular, convergent synthetic route to create potent and specific ‘synthetic biologic’ STRs that mimic the DNA binding domain of the active, spliced XBP1- 36 -SUBSTITUTE SHEET (RULE 26)homodimer. The inventors showed that stabilization of secondary and tertiary structural elements, identification of a core helical footprint within the parent bZIP TF, and alteration of interfacial contacts are necessary to create STRs with suitable biochemical and pharmacologic properties for DNA binding in cells. It was intriguing to see that dimerized helices from the native XBPls sequence do not strongly bind DNA, but that mutating two interfacial hydrophobic residues within the nascent leucine zipper core yields molecules that are potent DNA binders. Subsequent introduction of optimal secondary structure stabilization further improves affinity and specificity, as with STR22, and significantly increases the stability of STRs in cellular environments. While there remains room for the exploration and improvement of the STRs presented here, these data confirm that emergent properties can be realized through vigilant and layered structural stabilization of bZIP STRs, which is in agreement with recent studies of bHLH-derived STRs25. By comparison, TF mimetics consisting of large, natural polypeptide sequences alone pose nontrivial challenges in synthetic tractability and pharmacologic suitability. Perhaps most excitingly, the design principles developed here should be general to most or perhaps all bZIP TFs. This supposition is supported by the fact that no structures of XBPls exist, and yet the inventors were able to design STR22 from homology models of other bZIP TFs.
[0066] Optimized STRs, such as STR22, should prove to be valuable chemical probes to interrogate TF-DNA binding and transcriptional regulation, as well as prototype therapeutics. Here, the inventors reasoned that an XBPls-derived STR may be capable of targeting both UPRE- and HRE-DNA binding sites within cells due to the embedded HRE motif in the former sequence. The targeted and global ChIP and gene expression profiling studies presented here confirmed this hypothesis and raise intriguing questions about the normal and pathophysiologic crosstalk between these two TFs and their target gene networks. Most importantly, these data confirm that STR22 directly blocks HIFla binding to target HRE sites in the genome and specifically downregulates hypoxia-induced gene expression programs. This supports the notion that STRs can oppose the action of multiple oncogenic TFs by directly preventing DNA binding, which represents a mechanistically unique and potentially more powerful approach to attenuate pathologic gene expression in diseases like cancer. Along these lines, the recent approval of a small molecule inhibitor of HIF2a44in renal cancer underscores the therapeutic potential in targeting a genetically activated TF (due to VHL inactivation), and raises intriguing questions about the potential to target the expression programs regulated by multiple stress-responsive TFs, such as HIFla, HIF2a and XBPls, simultaneously with STRs. Furthermore, the results add mechanistic support for and provide additional therapeutic relevance to previous work implicating the co-regulation of HRE genes by XBPls and HIFla in TNBC15.- 37 -SUBSTITUTE SHEET (RULE 26)I. Engineered Peptides and DNA Binding DimersA. Engineered Peptides
[0067] Aspects of the present disclosure are directed to certain engineered peptides, including engineered bZIP peptides, as well as methods for making and using such engineered peptides, for example in the generation of DNA binding dimers. As used herein, an “engineered bZIP peptide” describes any peptide comprising an amino acid sequence from a portion of a bZIP protein. An engineered bZIP peptide may comprise an unmodified sequence of a region of a bZIP protein. In some aspects, an engineered bZIP peptide of the disclosure comprises a modified basic domain sequence from a bZIP protein. In some aspects, an engineered bZIP peptide of the disclosure comprises a modified leucine zipper domain sequence from a bZIP protein. In some cases an engineered bZIP peptide is a synthetic peptide having one or more modifications relative to a natural bZIP protein. For example, an engineered bZIP peptide may comprise a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more amino acid substitutions at any position relative to a natural bZIP protein sequence. Additionally or alternatively, an engineered bZIP peptide may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more chemical modifications. For example, an engineered bZIP peptide may comprise one or more modified amino acids (e.g., Lys(Mtt)), one or more non-natural amino acids (e.g., (S)-2-(4’- pentenyl)alanine), one or more intramolecular helix stabilizing linkers, one or more intrapeptide stabilizing linkages, one or more protecting groups, and / or other chemical modifications.
[0068] As used herein, a “modified basic domain sequence” of a bZIP protein describes an amino acid sequence which is modified in some way as compared to the natural sequence of the basic domain of the bZIP protein. Thus, for example, a “modified basic domain sequence” of the bZIP protein XBP1 is a sequence having one or more modifications as compared to the natural basic domain sequence of XBP1. Such modifications include, for example, removal of amino acids, amino acid substitutions (including substitutions with non-natural amino acids), and amino acid chemical modifications. In one example, a modified basic domain sequence of a bZIP protein is a sequence that is a portion of the natural basic domain sequence of the bZIP protein but does not comprise the full basic domain sequence. In another example, a modified basic domain sequence of a bZIP protein is a sequence having at least one amino acid substitution (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more substitutions) relative to the natural basic domain sequence of the bZIP protein. An amino acid substitution may be, for example, substitution for a different natural amino acid, substitution for a modified amino acid (e.g., Lys(Mtt)), or substitution for a non-natural amino acid (e.g., (S)-2-(4’-pentenyl)alanine). For example, where a natural basic domain for a human c-Fos protein has sequence- 38 -SUBSTITUTE SHEET (RULE 26)MKRRIRRERNKMAAAKCRNRRREL (SEQ ID NO: 108), a modified basic domain sequence of human c-Fos may be IRRERNKMAAAKSRNRRREC (SEQ ID NO: 16). Additional example modified basic domain sequences of c-Fos include IRR#RNK#AAAKSRNRRREC (SEQ ID NO: 17), EEKRRIRRERNKMAAAKSRNRRREC (SEQ ID NO: 18), and EEKRRIRR#RNK#AAAKSRNRRREC (SEQ ID NO: 19).
[0069] Example modified basic domain sequences are provided in Table 1, below.Table 1# is (S)-2-(4’-pentenyl)alanine orSUBSTITUTE SHEET (RULE 26)# are itrapeptide stabilizing linkage sites which together form the structure H
[0070] As used herein, a “modified leucine zipper domain sequence” of a bZIP protein describes an amino acid sequence which is modified in some way as compared to the natural sequence of the leucine zipper domain of the bZIP protein. Thus, for example, a “modified leucine zipper domain sequence” of the bZIP protein XBP1 is a sequence having one or more modifications as compared to the natural leucine zipper domain sequence of XBP1. Such modifications include, for example, removal of amino acids, amino acid substitutions (including substitutions with non-natural amino acids), and amino acid chemical modifications. In one example, a modified leucine zipper domain sequence of a bZIP protein is a sequence that is a portion of the natural leucine zipper domain sequence of the bZIP protein but does not comprise the full leucine zipper domain sequence of the bZIP protein. In another example, a modified leucine zipper domain sequence of a bZIP protein comprises a sequence having at least one amino acid substitution (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more substitutions) relative to the natural leucine zipper domain sequence of the bZIP protein. An amino acid substitution may be, for example, substitution for a different natural amino acid, substitution for a modified amino acid (e.g., Lys(Mtt)), or substitution for a non-natural amino acid (e.g., (S)- 2-(4’-pentenyl)alanine). For example, where a natural leucine zipper domain of human c-Fos has sequence TDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAH (SEQ ID NO: 109), a modified leucine zipper domain sequence of human c-Fos may be TDTLEDETDQLE (SEQ ID NO:20). Additional example modified leucine zipper domain sequences of human c-Fos include LDELQAEIEQLE (SEQ ID NO:21), IDELQAEIEQLE (SEQ ID NO:22), IDEIQAEIEQIE (SEQ ID NO:23), L#ELQ#EIEQLE (SEQ ID NO:24), I#ELQ#EIEQLE (SEQ ID NO:25), and I#EIQ#EIEQIE (SEQ ID NO:26).
[0071] Example modified leucine zipper domain sequences are provided in Table 2, below.Table 2- 40 -SUBSTITUTE SHEET (RULE 26)SUBSTITUTE SHEET (RULE 26)
[0072] Example engineered bZIP peptides contemplated herein and useful in compositions and methods of the present disclosure are provided in Table 3, below. Additional engineered bZIP peptides beyond those listed in Table 3 are contemplated herein.Table 3- 42 -SUBSTITUTE SHEET (RULE 26)Ac is acetyl; # is (S)-2-(4’-pentenyl)alanine; Kmis Lys(Mmt) or a Lys residue linked to a maleimide linker
[0073] FIGs. 21-98 show certain example synthetic dimers generated from engineered bZIP peptides.B. DNA Binding Dimers
[0074] Aspects of the present disclosure are directed to certain engineered DNA-binding dimers, including those generated from engineered bZIP peptides, along with methods of making and using such DNA-binding dimers. The DNA binding dimers include those described in PCT Application No. PCT / US2022 / 080387, which is specifically incorporated by reference herein in its entirety.1. Inter peptide Linkages
[0075] A bZIP transcriptional repressor of the disclosure is capable of binding to a bZIP protein binding site on DNA, as well as of competing with a natural (also “native”) bZIP protein for binding to the binding site. An interpeptide linkage may be any chemical linkage that covalently attaches two polypeptides (e.g., engineered bZIP peptides). In some aspects, at least one of the peptides comprise one or two (or more) linker residues. The interpeptide linkages include those described in PCT Application No. PCT / US2022 / 080387, which is specifically incorporated by reference herein in its entirety. In some aspects, one or more linker residue from one peptide are reacted with one or more linker residues from a second peptide to create an interpeptide linkage.- 43 -SUBSTITUTE SHEET (RULE 26)2. Intrapeptide Stabilizing Linkages
[0076] An engineered DNA-binding dimer may comprise one or more intrapeptide stabilizing linkages. In some aspects, intrapeptide stabilizing linkages can be hydrocarbon staples. “Stapling” as used herein, refers to a process by which two terminally unsaturated amino acid side chains in a polypeptide chain react with each other in the presence of a ring closing metathesis catalyst to generate an intrapeptide stablizing linkagebetween the two amino acids. In some aspects, the intrapeptide stabilizing linkages include those described in PCT Application No. PCT / US2022 / 080387, which is specifically incorporated by reference herein in its entirety.3. Examples of Peptides and Dimers
[0077] In some aspects, an engineered DNA-binding dimer of the disclosure has a particular affinity for binding to a region of DNA. In some aspects, the DNA-binding dimer binds to one or more regions of DNA comprising a particular motif. Examples include those described in PCT Application No. PCT / US2022 / 080387, which is specifically incorporated by reference herein in its entirety. Certain examples of bZIP transcriptional repressors of the disclosure are below:- 44 -SUBSTITUTE SHEET (RULE 26)
[0078] STR1SUBSTITUTE SHEET (RULE 26)
[0079] STR2SUBSTITUTE SHEET (RULE 26)
[0080] STR3SUBSTITUTE SHEET (RULE 26)
[0081] STR4SUBSTITUTE SHEET (RULE 26)
[0082] STR21SUBSTITUTE SHEET (RULE 26)
[0083] STR22SUBSTITUTE SHEET (RULE 26)
[0084] ASTR1SUBSTITUTE SHEET (RULE 26)
[0085] ASTR2SUBSTITUTE SHEET (RULE 26)
[0086] ASTR353SUBSTITUTE SHEET (RULE 26)
[0087] ASTR4SUBSTITUTE SHEET (RULE 26)
[0088] ASTR41SUBSTITUTE SHEET (RULE 26)
[0089] CASTR4SUBSTITUTE SHEET (RULE 26)
[0090] CASTR41SUBSTITUTE SHEET (RULE 26)
[0091] FJSTR1SUBSTITUTE SHEET (RULE 26)
[0092] FJSTR2SUBSTITUTE SHEET (RULE 26)
[0093] FJSTR3SUBSTITUTE SHEET (RULE 26)
[0094] FJSTR4SUBSTITUTE SHEET (RULE 26)
[0095] FJSTR5SUBSTITUTE SHEET (RULE 26)
[0096] FJSTR6SUBSTITUTE SHEET (RULE 26)
[0097] FJSTR7SUBSTITUTE SHEET (RULE 26)
[0098] FJSTR8SUBSTITUTE SHEET (RULE 26)
[0099] FJSTR9SUBSTITUTE SHEET (RULE 26)
[0100] FJSTR10SUBSTITUTE SHEET (RULE 26)
[0101] FJSTR31SUBSTITUTE SHEET (RULE 26)
[0102] FJSTR32SUBSTITUTE SHEET (RULE 26)
[0103] FJSTR71-70-SUBSTITUTE SHEET (RULE 26)
[0104] FJSTR72SUBSTITUTE SHEET (RULE 26)
[0105] FJSTR91-72-SUBSTITUTE SHEET (RULE 26)
[0106] FJSTR92SUBSTITUTE SHEET (RULE 26)
[0107] In some aspects, ASTRs (including ASTR1, ASTR3, ASTR2, ASTR4, and / or ASTR41) comprise a sequence from ATF4 that spans a defined region of basic and leucine zipper domain, and that is connected to a second monomer from the same ATF4 protein through a nonnatural side-by-side inter peptide linkage. In some aspects, CASTRs comprise a sequence from ATF4 that spans a defined region of basic and leucine zipper domain, and that is connected to a second monomer from the different CREB / P protein through a non-natural side-by-side inter peptide linkageII. Proteins
[0108] As used herein, a “protein” or “polypeptide” refers to a molecule comprising at least five amino acid residues. As used herein, a “peptide” refers to a molecule comprising at least three amino acid residues. As used herein, the term “wild-type” refers to the endogenous version of a molecule that occurs naturally in an organism. In some aspects, wild-type versions of a protein or polypeptide are employed, however, in many aspects of the disclosure, a modified protein or polypeptide is employed to generate an immune response. The terms described above may be used interchangeably. A “modified protein” or “modified polypeptide” “modified peptide” or a “variant” refers to a protein or polypeptide whose chemical structure, particularly its amino acid sequence, is altered with respect to the wild-type protein or polypeptide. In some aspects, a modified / variant protein or polypeptide has at least one modified activity or function (recognizing that proteins or polypeptides may have multiple activities or functions). It is specifically contemplated that a modified / variant protein or polypeptide may be altered with respect to one activity or function yet retain a wild-type activity or function in other respects.
[0109] Where a protein is specifically mentioned herein, it is in general a reference to a native (wild-type) or recombinant (modified) protein or, optionally, a protein in which any signal sequence has been removed. The protein may be isolated directly from the organism of which it is native, produced by recombinant DNA / exogenous expression methods, or produced by solidphase peptide synthesis (SPPS) or other in vitro methods. In particular aspects, there are isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences that encode a polypeptide (e.g., an antibody or fragment thereof). The term “recombinant” may be used in conjunction with a polypeptide or the name of a specific polypeptide, and this generally refers to a polypeptide produced from a nucleic acid molecule that has been manipulated in vitro or that is a replication product of such a molecule.
[0110] In certain aspects the size of a protein or polypeptide (wild-type or modified) may comprise, but is not limited to, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,- 74 -SUBSTITUTE SHEET (RULE 26)50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1100, 1200, 1300, 1400, 1500, 1750, 2000, 2250, 2500 amino acid residues or greater, and any range derivable therein, or derivative of a corresponding amino sequence described or referenced herein. The protein may comprise one or more proteins described in PCT Application No. PCT / US2022 / 080387, which is specifically incorporated herein by reference in its entirety It is contemplated that polypeptides may be mutated by truncation, rendering them shorter than their corresponding wild-type form, also, they might be altered by fusing or conjugating a heterologous protein or polypeptide sequence with a particular function (e.g., for targeting or localization, for enhanced immunogenicity, for purification purposes, etc.). As used herein, the term “domain” refers to any distinct functional or structural unit of a protein or polypeptide, and generally refers to a sequence of amino acids with a structure or function recognizable by one skilled in the art.[OHl] The polypeptides, proteins, or polynucleotides encoding such polypeptides or proteins of the disclosure may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivable range therein) or more variant amino acids or nucleic acid substitutions or be at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable range therein) similar, identical, or homologous with at least, or at most 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65,66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131,132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150,151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169,170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188,189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207,208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226,227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245,- 75 -SUBSTITUTE SHEET (RULE 26)246, 247, 248, 249, 250, 300, 350 or more contiguous amino acids or nucleic acids, or any range derivable therein, of SEQ ID NOs: 1-166.
[0112] In some aspects, the protein or polypeptide may comprise amino acids 1 to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107,108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126,127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145,146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164,165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183,184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221,222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240,241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259,260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278,279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297,298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316,317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335,336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, or 350 (or any derivable range therein) of SEQ ID NOs: 1-166.
[0113] 1. bZIP proteins
[0114] Aspects of the present disclosure comprise bZIP proteins, modified bZIP proteins, peptides from bZIP proteins, domains from bZIP proteins, and synthetic molecules comprising modified sequences from bZIP proteins. As used herein, a “bZIP protein” (also referred to herein as a “bZIP-containing transcription factor,” “bZIP transcription factor,” or “zTF”) describes any protein containing a basic leucine zipper region (also referred to herein as a “DNA binding region” of a bZIP protein) comprising two domains: a “basic domain” (also “basic region”), capable of direct interaction of the bZIP protein with DNA, and a “leucine zipper domain,” (also “dimerization domain,” “leucine zipper region,” or “leucine zipper”), capable of dimerization with another bZIP protein. A bZIP protein may be a human (Homo sapiens) bZIP protein or may be a non-human bZIP protein. Various examples of bZIP proteins are recognized in the art and described in, for example, Miller M. Curr Protein P ept Set. 2009;10(3):244-269; Ramji DP, Foka- 76 -SUBSTITUTE SHEET (RULE 26)P. Biochem J. 2002;365(Pt 3):561-575; Wagner EF. Oncogene. 2001;20(19):2334-2335; Hai T, Hartman MG. Gene. 2001;273(l): 1-11; Bailey D, O'Hare P. Antioxid Redox Signal. 2007;9(12):2305-2321; Hunger SP, et al., Blood. 1996;87(1 l):4607-4617; Blank V, Andrews NC. Trends Biochem Sci. 1997;22(11):437-441; Motohashi H, et al., Gene. 2002;294(l-2): l-12; all of which are incorporated herein by reference in their entirety.2. HIF proteins
[0115] Aspects of the present disclosure are related to one or more hypoxia-inducible factor (HIF) proteins. HIF proteins include, but are not limited to, HIFla (also “HIF-la”), HIF2a (also “HIF-2a”), HIF3a (also “HIF-3a”), and HIFip (also “HIF-ip”). HIF proteins are transcription factors recognized as regulators of the cellular response to hypoxia. Certain aspects of the disclosure relate to one or more HIF protein target genes, i.e., genes whose expression is regulated by a HIF transcription factor (e.g., HIF-1). Disclosed, in some aspects, are compositions and methods useful in reducing expression of a HIF protein target gene.3. bHLH proteins
[0116] Certain aspects of the present disclosure are related to one or more proteins containing a basic helix-loop-helix domain. Members of this family include the Myc oncoproteins, their binding partner Max, and the mammalian transcription factors USF, TFE3, and TFEB. Also provided herein are stapled polypeptides comprising synthetic DNA-binding domains (sDBDs) that mimic the DNA-binding domains of basic helix-loop-helix (bHLH) transcription factors and methods of using such peptides as therapeutic agents. For example, in some aspects, provided herein is a synthetic DNA binding domain peptide, comprising: a synthetically modified peptide that binds to a DNA molecule (e.g., a DNA comprising an E-box transcription factor binding site or other DNA binding site), wherein the peptide comprises a dimerization moiety configured to form a dimer with a second modified peptide. The present disclosure is not limited to particular dimerization moieties.4. Sequences
[0117] Example amino acid and nucleotide sequences for various polypeptides, peptides, and nucleic acids of the disclosure are provided in Table 6 below.Table 6- 77 -SUBSTITUTE SHEET (RULE 26)-78 -SUBSTITUTE SHEET (RULE 26)-79-SUBSTITUTE SHEET (RULE 26)- 80 -SUBSTITUTE SHEET (RULE 26)- 81 -SUBSTITUTE SHEET (RULE 26)- 82 -SUBSTITUTE SHEET (RULE 26)# = (S)-2-(4’-pentenyl)alanine* = Lys(Mmt)III. Nanoparticles
[0118] Certain aspects disclosed herein concern compositions comprising a nanoparticle, which may encapsulate a therapeutic agent, which can be any of the therapeutic agents disclosed herein. The nanoparticle compositions may encapsulate therapeutic agents, which may be engineered protein compositions. The engineered proteins formulated in the nanoparticles can have improved pharmacokinetic and / or pharmacodynamic properties. The engineered proteins formulated in the nanoparticles are better tolerated by a patient, including a cancer patient. The engineered proteins formulated in the nanoparticles, in some aspects, are more effectively delivered to cells to effect their function, such as effecting transcriptional changes, than naked engineered proteins. In several aspects, the composition confers water solubility to hydrophobic agents, to combinations of hydrophobic agents, and / or to combinations of hydrophobic and hydrophilic agents. In several aspects, the nanoparticle composition comprises a liposomal and / or nano-emulsion composition of a therapeutic agent.- 83 -SUBSTITUTE SHEET (RULE 26)
[0119] In several aspects, as disclosed elsewhere herein, a nanoparticle composition (e.g., a mixed micelle composition, a liposomal composition, solid lipid particles, oil-in-water emulsions, water-in-oil-in-water emulsions, water-in-oil emulsions, oil-in-water-in-oil emulsions, etc.) is provided to aid in the delivery of therapeutic agents. As disclosed elsewhere herein, in several aspects, the nanoparticles comprise one or more therapeutic agents. In several aspects, a composition comprising the nanoparticles disclosed herein comprises a therapeutically effective amount of one or more therapeutic agents.
[0120] In several aspects, when formulated, the dry weight % of one or more therapeutic agents present in the nanoparticle compositions is equal to or at least about: 0.1%, 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, or any ranger derivable therein. In several aspects, the therapeutic agents are provided in an aqueous composition. In several aspects, the wet weight % of one or more therapeutic agents present in the composition (with water included) is equal to or at least about: 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, or any range derivable therein. In several aspects, the one or more therapeutic agents may be provided in the wet composition at a concentration of greater than or equal to about: 0.001 mg / mL, 0.005 mg / mL, 0.01 mg / mL, 0.05 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 5 mg / mL, 20 mg / mL, 30 mg / mL, 50 mg / mL, 100 mg / mL, or any range derivable therein.
[0121] In several aspects, the therapeutic agents, collectively or individually, are present in the aqueous nanoparticle composition at a concentration of less than or equal to about: 150 mg / mL, 100 mg / mL, 75 mg / mL, 50 mg / mL, 25 mg / mL, 20 mg / mL, 10 mg / mL, 5 mg / mL, 2.5 mg / mL, 2 mg / mL, 1.5 mg / mL, 1 mg / mL, 0.5 mg / mL, 0.1 mg / mL, 0.05 mg / mL, 0.01 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more therapeutic agents, collectively or individually, are present in the aqueous composition at a concentration of greater than or equal to about: 150 mg / mL, 100 mg / mL, 75 mg / mL, 50 mg / mL, 25 mg / mL, 20 mg / mL, 10 mg / mL, 5 mg / mL, 2.5 mg / mL, 2 mg / mL, 1.5 mg / mL, 1 mg / mL, 0.5 mg / mL, 0.1 mg / mL, 0.05 mg / mL, 0.01 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more therapeutic agents, collectively or individually, are present in the composition at a dry wt. % of equal to or at least about: 0.1%, 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more therapeutic agents, collectively or individually, are present in the composition at a wet wt. % of equal to or at least about: 0.1%, 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, or ranges including and / or- 84 -SUBSTITUTE SHEET (RULE 26)spanning the aforementioned values. In several aspects, as disclosed elsewhere herein, the composition is aqueous, while in others it has been dried into a powder (that is free of or substantially free of water). In several aspects, where the composition has been dried, it comprises a water content of less than or equal to 20%, 15%, 10%, 7.5%, 5%, 2.5%, 1%, or ranges including and / or spanning the aforementioned values.
[0122] In several aspects, as disclosed elsewhere herein, the composition is aqueous (e.g., contains water) while in other aspects, the composition is dry (lacks water or substantially lacks water). In several aspects, the composition has been dried (e.g., has been subjected to a process to remove most or substantially all water). In several aspects, the composition comprises nanoparticles in water (e.g., as a solution, suspension, or emulsion). In other aspects, the composition is provided as a powder (e.g., that may be constituted or reconstituted in water). In several aspects, as disclosed elsewhere herein, the water content (in wt. %) of the composition is less than or equal to about: 30%, 20%, 10%, 5%, 2.5%, 1%, 0.5%, 0.1%, 0%, or ranges including and / or spanning the aforementioned values. In several aspects, as disclosed elsewhere herein, the water content (in wt. %) of the composition is greater than or equal to about: 50%, 60%, 70%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, or ranges including and / or spanning the aforementioned values. In several aspects, the water is nanopure, deionized, USP grade, WFI, and / or combinations of the foregoing. In some aspects, the composition is a dried composition comprising a nanoparticle having weight ratios of a first therapeutic agent: a nanoscale coordination polymer (NCP): optionally a lipid source, and optionally a surfactant of 1 to 50: 1 to 50: 1 to 50:0 to 17.5.
[0123] In several aspects, as disclosed elsewhere herein, the nanoparticle composition provides an oil-in-water emulsion (e.g., a nanoemulsion), water-in-oil emulsion, a water-in-oil-in- water emulsion, an oil-in-water-in-oil emulsion, a liposome (and variants including multi-lamellar, double liposome preparations, etc.), micelle, and / or solid lipid particles. Any one of these structures may be provided as a nanoparticle or microparticle.
[0124] As disclosed elsewhere herein, in some aspects, the nanoparticle composition comprises a lipid source. In several aspects, the lipid source comprises a charged lipid, which can impart a charge to the nanoparticle. In several aspects, the lipid source comprises a neutral lipid. In several aspects, the lipid source comprises one or more phospholipids. In several aspects, the one or more phospholipids comprises one or more of phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylinositol phosphate, phosphatidylinositol bisphosphate, phosphatidylinositol trisphosphate, lipoid H 100-3, phospholipon 90H, phospholipon 80H, lipoid 100-3, lipoid P75-3, l,2-dioleoyl-sn-glycero-3 -phosphate (DOPA), l,2-dioleoyl-sn-glycero-3-phosphocholine(DOPC), l,2-diastearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene- 85 -SUBSTITUTE SHEET (RULE 26)glycol)2000] (DSPE-PEG2000) or any combination of the foregoing. In several aspects, the lipid source is a phosphatidylcholine. In several aspects, the one or more lipid source lipid(s) (collectively or individually) are present in the composition at a dry wt. % of equal to or less than about: 0%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more lipid source lipid(s) (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0%, 0.1%, 0.5%, 1.0%, 2.5%, 4%, 5%, 6%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more lipid source lipid(s) (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7.5 mg / mL, 10 mg / mL, 12.5 mg / mL, 15 mg / mL, 17.5 mg / mL, 20 mg / mL, 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, 50 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, as disclosed elsewhere herein, the composition is aqueous, while in others it has been dried into a powder. For instance, as disclosed elsewhere herein, in several aspects, the composition is aqueous (wet), while in others it has been dried into a powder (dry). In several aspects, the one or more lipid(s) of the lipid source are synthetic, derived from sunflower, soy, egg, or mixtures thereof. In several aspects, the one or more lipids of the lipid source can be hydrogenated or nonhydrogenated. In several aspects, the lipid source exceeds requirements of the United States Pharmacopeia (is USP grade) and / or is National Formulary (NF) grade.
[0125] In several aspects, the one or more lipids of the lipid source has a purity of greater than or equal to about: 92.5%, 95%, 96%, 96.3%, 98%, 99%, 100%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more lipids of the lipid source has a total % impurity content by weight of less than or equal to about: 8.5%, 5%, 4%, 3.7%, 2%, 1%, 0%, or ranges including and / or spanning the aforementioned values.
[0126] As disclosed elsewhere herein, in some aspects, the nanoparticle composition comprises a surfactant. In certain aspects, the nanoparticle composition does not comprise a surfactant. In several aspects, the surfactant is a pharmaceutically acceptable surfactant. In several aspects, the surfactant is a food surfactant. In several aspects, the surfactant comprises one or more of a polyoxyethylene sorbitan esters (e.g., polysorbates / tweens, including polysorbate 80, polysorbate 20, etc.), cremophor (e.g., a non-ionic solubilizer and emulsifier that is made by reacting ethylene oxide with castor oil), propylene oxide-modified polymethylsiloxane, dodecyl betaine, lauramidopropyl betaine, cocoamido-2-hydroxypropyl sulfobetaine, sodium stearate (or other stearate salts), polyoxyethylene alcohol, lecithins, mono- and diglycerides of fatty acids (MDG), acetic acid esters of MDG, lactic acid esters of MDG, citric acid esters of MDG, mono-- 86 -SUBSTITUTE SHEET (RULE 26)and diacetyl tartaric acid esters of MDG, sucrose esters of fatty acids, polyglycerol esters of fatty acids (e.g., polyglycerol esters), polyglycerol polyricinoleate, propane- 1,2-diol esters of fatty acids, propylene glycol esters, sodium stearoyl-2-lactylate, calcium stearoyl-2-lactylate, sorbitan fatty acid esters, quillaj a extract surfactant, yucca extract surfactant, saponins, silicone emulsifiers, sorbitan trioleate, soya lecithin, dioctyl sodium sulfosuccinate, dioctyl sodium sulfonate, polyoxyethylene, hydrogenated castor oil, sucrose fatty acid ester, or combinations of any of the foregoing. Natural or synthetic surfactants can be used, including polyethylene glycol and dextrans, such as cyclodextran. In several aspects, the one or more surfactants are present in the nanoparticle composition (collectively or individually) at a dry wt. % of equal to or less than about: 0%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, or ranges including and / or spanning the aforementioned values. Surfactants can include cationic, anionic, non-ionic, and zwitterionic surfactants. In several aspects, the one or more surfactants (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0%, 0.1%, 0.5%, 1.0%, 2.5%, 4%, 5%, 6%, 7.5%, 10%, 12.5%, 15%, 17.5%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more surfactants (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7.5 mg / mL, 10 mg / mL, 12.5 mg / mL, 15 mg / mL, 17.5 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, the surfactant exceeds requirements of the United States Pharmacopeia (is USP grade) and / or is National Formulary (NF) grade.
[0127] In several aspects, one or more co-emulsifiers are used. In certain aspects, the nanoparticle composition does not comprise a co-emulsifer. In several aspects, the co-emulsifier is a pharmaceutically acceptable co-emulsifier. In several aspects, the co-emulsifier is selected from the group consisting of oleic acid, miglyol 812N (all versions), cetearyl olivate, isoprpyle myristate, celluloses, polysaccharides (e.g., methylcellulose, propylmethylcellulose, hydroxypropyl methylcellulose, xanthan gum, etc.), capric acid, caprylic acid, triglycerides (e.g., triglycerides of oleic acid, capric acid, caprylic acid (Captex 8000, Captex GTO, Captex 1000)), glycerol monooleate, glyceryl stearate, glycerol monostearate (Geleol™ Mono and Diglyceride NF), omega-3 fatty acids (a-linolenic acid (ALA), eicosapentaenoic acid (EP A), docosahexaenoic acid (DHA), Tonalin, Pronova Pure® 46:38, free fatty acid Tonalin FFA 80), conjugated linoleic acid (CLA), alpha glycerylphosphorylcholine (alpha GPC), palmitoylethanolamide (PEA), cetyl alcohol, or emulsifying wax and / or combinations of any of the foregoing. In several aspects, the one or more co-emulsifiers are present in the nanoparticle composition (collectively or individually) at a dry wt. % of equal to or less than about: 0%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, or ranges including and / or spanning the aforementioned values. In several aspects, the- 87 -SUBSTITUTE SHEET (RULE 26)one or more co-emulsifiers (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0%, 0.1%, 0.5%, 1.0%, 2.5%, 4%, 5%, 6%, 7.5%, 10%, 12.5%, 15%, 17.5%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more co-emulsifiers (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7.5 mg / mL, 10 mg / mL, 12.5 mg / mL, 15 mg / mL, 17.5 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, the co-emulsifiers exceeds requirements of the United States Pharmacopeia (is USP grade) and / or is National Formulary (NF) grade. In some aspects, the co-emulsifier component comprises a medium chain triglyceride (MCT). In some aspects, the medium chain triglyceride comprises a fatty acid selected from one or more of caprioc acid, octanoic acid, capric acid, caprylic acid, and / or lauric acid (e.g., is formed from). In some aspects, the medium chain triglyceride comprises a fatty acid 6-12 carbons in length (e.g., 6, 7, 8, 9, 10, 11, or 12). In some aspects, the co-emulsifier component comprises a long chain triglyceride (LCT). In some aspects, the long chain triglyceride comprises a fatty acid greater than 12 carbons in length (e.g., greater than or equal to 13, 14, 15, 16, 17, 18, 19, or 20 carbons in length, or ranges including and / or spanning the aforementioned values). In some aspects, the co-emulsifier component is a single lipid. In some aspects, the co- emulsifier component is highly pure. In some aspects, the co-emulsifier component has a purity by weight % of equal to or greater than about: 90%, 95%, 97%, 98%, 99%, 100%, or ranges including and / or spanning the aforementioned values. In some aspects, the co-emulsifier component is present in the nanoparticle composition at dry weight % of equal to or greater than about: 10%, 20%, 30%, 35%, 40%, 45%, 50%, or ranges including and / or spanning the aforementioned values.
[0128] In some aspects, the nanoparticle composition comprises one or more sterols. In certain aspects, the nanoparticle composition does not comprise a sterol. In some aspects, the one or more sterols comprises one or more cholesterols, ergosterols, hopanoids, hydroxysteroids, phytosterols (e.g., vegapure), ecdysteroids, and / or steroids. In some aspects the sterol comprises a cholesterol. In some aspects, the sterol component is a single sterol. In some aspects, the sterol component is cholesterol. In some aspects, the cholesterol (or other sterol) is highly pure. In some aspects, the one or more sterol(s) (e.g., cholesterol, and / or other sterols), collectively or individually, are present in the aqueous composition at a concentration of less than or equal to about: 50 mg / mL, 40 mg / mL, 20 mg / mL, 10 mg / mL, 5 mg / mL, or ranges including and / or spanning the aforementioned values. In some aspects, the one or more sterol(s) are present in the composition at a dry wt. % of equal to or less than about: 0.25%, 0.5%, 1%, 5%, 7.5%, 10%, 15%, 20%, 25%, or ranges including and / or spanning the aforementioned values. In some aspects, the one or more- 88 -SUBSTITUTE SHEET (RULE 26)sterol(s) (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.1%, 0.25%, 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, or ranges including and / or spanning the aforementioned values. In some aspects, the cholesterol used in the composition comprises cholesterol from one or more of sheep’s wool, synthetic cholesterol, or semisynthetic cholesterol from plant origin. In some aspects, the sterol has a purity of greater than or equal to about: 92.5%, 95%, 96%, 98%, 99%, 99.9%, 100.0%, or ranges including and / or spanning the aforementioned values. In some aspects, the sterol has a total % impurity content by weight of less than or equal to about: 8.5%, 5%, 4%, 3.7%, 2%, 1%, 0%, or ranges including and / or spanning the aforementioned values. In some aspects, the sterol is not cholesterol.
[0129] In several aspects, the nanoparticle composition comprises a preservative. In certain aspects, the nanoparticle composition does not comprise a preservative. In several aspects, the preservative includes one or more benzoates (such as sodium benzoate or potassium benzoate), nitrites (such as sodium nitrite), sulfites (such as sulfur dioxide, sodium or potassium sulphite, bisulphite or metabisulphite), sorbates (such as sodium sorbate, potassium sorbate), ethylenediaminetetraacetic acid (EDTA) (and / or the disodium salt thereof), polyphosphates, organic acids (e.g., citric, succinic, malic, tartaric, benzoic, lactic and propionic acids), and / or antioxidants (e.g., vitamins such as vitamin E and / or vitamin C, butylated hydroxytoluene). In several aspects, sorbates and benzoates may be used in acidic pH formulations. In several aspects, the one or more preservatives (collectively or individually) are present in the composition at a dry wt. % of equal to or at less than about: 0.01%, 0.1%, 0.25%, 0.5%, 1%, 5%, 7.5%, 10%, 15%, 20%, 25%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more preservatives (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.001%, 0.01%, 0.025%, 0.05%, 0.1%, 0.5%, 0.75%, 1.0%, 1.5%, 2.0%, 2.5%, 5%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more preservatives (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.001 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, as disclosed elsewhere herein, the composition is aqueous, while in others it has been dried into a powder. For instance, as disclosed elsewhere herein, in several aspects, the composition is aqueous (wet), while in others it has been dried into a powder (dry). In several aspects, the preservatives inhibit or prevent growth of mold, bacteria, and fungus.
[0130] In some aspects, the nanoparticle composition comprises a metal. The metal may be zinc. In certain aspects, the nanoparticle composition does not comprise a metal. In several aspects, the one or more metals (collectively or individually) are present in the composition at a dry wt. % of equal to or at less than about: 0.01%, 0.1%, 0.25%, 0.5%, 1%, 5%, 7.5%, 10%, 15%,- 89 -SUBSTITUTE SHEET (RULE 26)20%, 25%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more metals (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.001%, 0.01%, 0.025%, 0.05%, 0.1%, 0.5%, 0.75%, 1.0%, 1.5%, 2.0%, 2.5%, 5%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more metals (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.001 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, or ranges including and / or spanning the aforementioned values. The metals may be combined with metalloligands to generate a nanoscale coordination polymer. Nanoscale coordination polymers may comprise metal-connecting points and organic bridging ligands. The nanoscale coordination polymers (NCP) may self-assemble into nanoparticles.
[0131] In several aspects, as disclosed elsewhere herein, the nanoparticle composition provides particles in the nano-measurement range. In several aspects, the nanoparticle is spherical or substantially spherical. In several aspects, a solid lipid nanoparticle possesses a solid lipid core matrix that can solubilize lipophilic molecules. In several aspects, the lipid core is stabilized by surfactants and / or emulsifiers as disclosed elsewhere herein, while in other aspects, surfactants are absent. In several aspects, the size of the particle is measured as a mean diameter. In several aspects, the size of the particle is measured by dynamic light scattering. In several aspects, the size of the particle is measured using a zeta-sizer. In several aspects, the size of the particle can be measured using Scanning Electron Microscopy (SEM). In several aspects, the size of the particle is measured using a cyrogenic SEM (cryo-SEM). Where the size of a nanoparticle is disclosed elsewhere herein, any one or more of these instruments or methods may be used to measure such sizes.
[0132] In several aspects, the nanoparticle composition comprises nanoparticles having an average size of less than or equal to about: 10 nm, 25 nm, 40 nm, 50 nm, 100 nm, 250 nm, 500 nm, 1000 nm, or ranges including and / or spanning the aforementioned values. In several aspects, the composition comprises nanoparticles having an average size of between about 50 nm and 150 nm or between about 50 and about 250 nm. In several aspects, the size distribution of the nanoparticles for at least 50%, 75%, 80%, 90% (or ranges including and / or spanning the aforementioned percentages) of the particles present is equal to or less than about: 20 nm, 40 nm, 60 nm, 80 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, 300 nm, 400 nm, 500 nm, or ranges including and / or spanning the aforementioned nm values. In several aspects, the composition comprises nanoparticles having an average size of less than or equal to about: 10 nm, 50 nm, 100 nm, 250 nm, 500 nm, 1000 nm, or ranges including and / or spanning the aforementioned values. In several aspects, the size distribution of the nanoparticles for at least- 90 -SUBSTITUTE SHEET (RULE 26)110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, 300 nm, 400 nm, 500 nm, or ranges including and / or spanning the aforementioned nm values. In several aspects, the size distribution of the nanoparticles for at least 90% of the particles present is equal to or less than about: 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, or ranges including and / or spanning the aforementioned nm values. In several aspects, the D90 of the particles present is equal to or less than about: 80 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, 300 nm, 400 nm, 500 nm, or ranges including and / or spanning the aforementioned values. In several aspects, the size of the nanoparticle is the diameter of the nanoparticle as measured using any of the techniques as disclosed elsewhere herein. For instance, in some aspects, the size of the nanoparticle is the measured using dynamic light scattering. In several aspects, the size of the nanoparticle is the measured using a zeta sizer. In several aspects, consistency in size over time, or within a sample, allows predictable stability for the active agent encapsulated therein.
[0133] In several aspects, over 50%, 75%, 95% (or ranges spanning and or including the aforementioned values) of the nanoparticles prepared by the methods disclosed herein have a particle size of between about 20 to about 500 nm (as measured by zeta sizing (e.g., refractive index). In several aspects, over 50%, 75%, 95% (or ranges spanning and or including the aforementioned values) of the nanoparticles prepared by the methods disclosed herein have a particle size of between about 50 nm to about 200 nm (as measured by zeta sizing (e.g., refractive index). In several aspects, over 50%, 75%, 95% (or ranges spanning and or including the aforementioned values) of the nanoparticles prepared by the methods disclosed herein have a particle size of between about 90 nm to about 150 nm (as measured by zeta sizing (e.g., refractive index). In several aspects, this consistency in size allows predictable delivery to subjects. In several aspects, the D90 particle size measurement varies between 150 and 500 nm.
[0134] In several aspects, the average size of the nanoparticles of a composition as disclosed herein is substantially constant and / or does not change significantly over time (e.g., it is a stable nanoparticle). In several aspects, after formulation and storage for a period of at least about 1 month (30 days), about 3 months (90 days), or about 6 months (180 days) (e.g., at ambient conditions, at 25°C with 60% relative humidity, or under the other testing conditions disclosed elsewhere herein), the average size of nanoparticles comprising the composition changes less than or equal to about: 1%, 5%, 10%, 20%, or ranges including and / or spanning the aforementioned values.
[0135] In several aspects, the poly dispersity index (PDI) of the nanoparticles of a composition as disclosed herein is less than or equal to about: 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, or ranges including and / or spanning the aforementioned values. In several aspects, the- 91 -SUBSTITUTE SHEET (RULE 26)size distribution of the nanoparticles is highly monodisperse with a poly dispersity index of less than or equal to about: 0.05, 0.10, 0.15, 0.20, 0.25, or ranges including and / or spanning the aforementioned values.
[0136] In several aspects, the zeta potential of the nanoparticles of a composition as disclosed herein is less than or equal to about: 1 mV, 3 mV, 4 mV, 5 mV, 6 mV, 7 mV, 8 mV, 10 mV, 20 mV, or ranges including and / or spanning the aforementioned values. In several aspects, the zeta potential of the nanoparticles is greater than or equal to about: -3 mV, -1 mV, 0 mV, 1 mV, 3 mV, 4 mV, 5 mV, 6 mV, 7 mV, 8 mV, 4 mV, 10 mV, 20 mV, or ranges including and / or spanning the aforementioned values. In several aspects, the zeta potential and / or diameter of the particles (e.g., measured using dynamic light scattering) is acquired using a zetasizer (e.g., a Malvern ZS90 or similar instrument).
[0137] In several aspects, as disclosed elsewhere herein, the nanoparticle composition is an oil-in-water emulsion, water-in-oil emulsion, water-in-oil-in-water emulsion, oil-in-water-in-oil emulsion, liposome, solid lipid particles formulation, etc. For brevity, these may just be referred to as the composition. In several aspects, the nanoparticle composition can be processed to comprises one or more of solid lipid nanoparticles, liposomes (and variants including multi- lamellar, double liposome preparations, etc.), niosomes, ethosomes, electrostatic particulates, microemulsions, nanoemulsions, microsuspensions, nanosuspensions, or combinations thereof. In several aspects, polymeric nanoparticles may be formed. In several aspects, cyclodextrin is added.
[0138] In several aspects, a solid lipid nanoparticle compositions comprises a lipid core matrix. In several aspects, the lipid core matrix is solid. In several aspects, the solid lipid comprises one or more ingredients as disclosed elsewhere herein. In several aspects, the core of the solid lipid comprises one or more lipids, surfactants, active ingredients, etc. In several aspects, the surfactant acts as an emulsifier. In several aspects, emulsifiers can be used to stabilize the lipid dispersion (with respect to charge and molecular weight). In several aspects, the core ingredients (e.g., the components of the core) are present in the composition (collectively or individually) at a dry wt. % of equal to or less than about: 0.5%, 1.0%, 2.5%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 80% or ranges including and / or spanning the aforementioned values. In several aspects, the core ingredients and / or the emulsifiers (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.5%, 1.0% 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 30%, 40%, 60% or ranges including and / or spanning the aforementioned values.
[0139] In several aspects, the nanoparticle composition (e.g., when in water or dried) comprises multilamellar nanoparticle vesicles, unilamellar nanoparticle vesicles, multivesicular nanoparticles, emulsion particles, irregular particles with lamellar structures and bridges, partial emulsion particles, combined lamellar and emulsion particles, and / or combinations thereof. In- 92 -SUBSTITUTE SHEET (RULE 26)certain aspects, the nanoparticle compositions do not comprise multilamellar nanoparticle vesicles, unilamellar nanoparticle vesicles, multivesicular nanoparticles, emulsion particles, irregular particles with lamellar structures and bridges, partial emulsion particles, combined lamellar and emulsion particles, and / or combinations thereof. In several aspects, the composition is characterized by having multiple types of particles (e.g., lamellar, emulsion, irregular, etc.). In other aspects, a majority of the particles present are emulsion particles. In several aspects, a majority of the particles present are lamellar (multilamellar and / or unilamellar). In other aspects, a majority of the particles present are irregular particles. In still other aspects, a minority of the particles present are emulsion particles. In several aspects, a minority of the particles present are lamellar (multilamellar and / or unilamellar). In other aspects, a minority of the particles present are irregular particles.
[0140] In several aspects, multilamellar nanoparticles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 5% and about 10% of the particles present are multilamellar. In several aspects, unilamellar nanoparticles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 20%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 10% and about 15% of the particles present are unilamellar.
[0141] In several aspects, emulsion particles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 60%, 65%, 70%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 60% to about 75% of the particles present are emulsion particles.
[0142] In several aspects, micelle particles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 60%, 65%, 70%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition).
[0143] In several aspects, liposomes comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 60%, 65%, 70%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition).
[0144] In several aspects, irregular particles (including particles with lamellar structures and / or bridges) comprise equal to or at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%,- 93 -SUBSTITUTE SHEET (RULE 26)15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 1% to about 5% of the particles present are irregular particles.
[0145] In several aspects, combined lamellar and emulsion particles comprise equal to or at least about 5%, 6%, 7%, 8%, 9%, 10%, 15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition).
[0146] In several aspects, mixed-micelle particles comprise equal to or at least about 5%, 6%, 7%, 8%, 9%, 10%, 15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition).
[0147] The nanoparticle compositions can comprise, but are not limited to, combinations of multilamellar nanoparticles, unilamellar nanoparticles, emulsion nanoparticles, micelle nanoparticles, irregular particles, and / or liposomes.
[0148] The percentages and / or concentrations of particles present in the composition may be purposefully modified. In some aspects, the percentage and / or concentration of the particles present in the composition are tailored to the active compound and / or the liquid comprising the particles. Such tailoring may lead to more homogenization and / or dispersion in the liquid. The tailoring may stabilize dispersion in the liquid.
[0149] In several aspects, the formulations and / or compositions disclosed herein are stable during sterilization. In several aspects, the sterilization may include one or more of ozonation, UV treatment, and / or heat treatment. In several aspects, the particle size and / or PDI after sterilization (e.g., exposure to techniques that allow sterilization of the composition) varies by less than or equal to about: 1%, 5%, 10%, 20%, 30%, or ranges including and / or spanning the aforementioned values. In several aspects, the therapeutic agent concentration after sterilization (e.g., exposure to techniques that allow sterilization of the composition) varies (e.g., drops) by less than or equal to about: 1%, 5%, 10%, 15%, or ranges including and / or spanning the aforementioned values.
[0150] In several aspects, the nanoparticle compositions (including after stabilization) disclosed herein have a shelf life of equal to or greater than 1 month, 3 months, 6 months, 12 months, 14 months, 16 months, 18 months, 19 months, or ranges including and / or spanning the aforementioned values. The shelf-life can be determined as the period of time in which there is 95% confidence that at least 50% of the response (active agent(s) concentration or particle size) is within the specification limit. This refers to a 95% confidence interval and when linear regression predicts that at least 50% of the response is within the set specification limit.- 94 -SUBSTITUTE SHEET (RULE 26)IV. Administration of Therapeutic Compositions
[0151] Aspects of the present disclosure are directed to treatment or prevention of one or more diseases or conditions. In particular aspects, the present disclosure related to treatment or prevention of a disease or condition affected by expression of a gene under the control of a bZIP transcription factor (e.g., a bZIP transcription factor described or incorporated herein). For example, a condition of the disclosure may be a condition where overexpression of a gene under the control of a bZIP transcription factor contributes to the condition. Such conditions include, but are not limited to, cancer, fibrotic disorders, and diabetes. Therapeutic agents of the disclosure (e.g., bZIP transcriptional repressors formulated in nanoparticle compositions) may be administered by one or more routes of administration. In some aspects, a nanoparticle composition is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In some aspects, a bZIP transcriptional repressor is administered intraveneously. The appropriate dosage may be determined based on the type of disease to be treated, severity and course of the disease, the clinical condition of the individual, the individual's clinical history and response to the treatment, and the discretion of the attending physician.
[0152] In several aspects, as disclosed elsewhere herein, the nanoparticle composition aids in absorption, bioavailability, or other pharmacokinetic properties of the active compound when administered to an individual, including by orally ingestion. In several aspects, the compositions disclosed herein allow the active compound to be delivered to and / or absorbed through the gut. As disclosed elsewhere herein, some aspects pertain to the use of the nanoparticle based nanodelivery system to protect the active compound from degradation and / or precipitation in a solution comprising the active compound (e.g., in an aqueous composition for administration to a subject). In several aspects, use of the delivery systems, including the nanoparticles, disclosed herein result in improved bioavailability and / or absorption rate. For instance, in some aspects, the Cmax of an active compound is increased using a disclosed aspect, the Tmax of an active compound is decreased using an aspect as disclosed herein, and / or the AUC of an active compound is increased using a disclosed aspect.
[0153] In several aspects, the pharmacokinetic outcomes disclosed elsewhere herein (Cmax, Tmax, AUC, ti / 2, etc.) can be achieved using aqueous nanoparticle compositions or powdered nanoparticle compositions (e.g., where the powder is supplied by itself, in a gel capsule, as an additive to food, etc.).
[0154] In several aspects, the Cmax of the active agent is increased using the disclosed aspects relative to other delivery vehicles (e.g., after administration to a subject). In several aspects, the- 95 -SUBSTITUTE SHEET (RULE 26)Cmax is increased relative to the active agent alone or comparator aspects (e.g., oil-based products) by equal to or at least about: 15%, 20%, 50%, 100%, 150%, 200%, or ranges including and / or spanning the aforementioned values. In several aspects, the active agent Cmax is increased (relative to a comparator oil-based product) by equal to or at least about: 5%, 10%, 20%, 30%, 50%, 100%, or ranges including and / or spanning the aforementioned values. In several aspects, the active agent Cmax is increased (relative to a comparator oil-based product) by equal to or at least about: 10 ng / mL, 20 ng / mL, 30 ng / mL, 40 ng / mL, 50 ng / mL, 60 ng / mL, 70 ng / mL, 80 ng / mL, 90 ng / mL, or ranges including and / or spanning the aforementioned values.
[0155] The treatments may include various “unit doses.” Unit dose is defined as containing a predetermined-quantity of the therapeutic composition. The quantity to be administered, and the particular route and formulation, is within the skill of determination of those in the clinical arts. A unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time. In some aspects, a unit dose comprises a single administrable dose.
[0156] In some aspects, a therapeutic agent (e.g., a bZIP transcriptional repressor, a bHLH transcriptional repressor) is administered in a nanoparticle composition at a dose of between 1 mg / kg and 5000 mg / kg. In some aspects, the therapeutic agent is administered in a nanoparticle composition at a dose of at least, at most, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133,134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152,153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171,172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190,191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247,248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266,267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285,286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304,305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323,324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342,343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361,362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380,- 96 -SUBSTITUTE SHEET (RULE 26)381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399,400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418,419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437,438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456,457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475,476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513,514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532,533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551,552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570,571, 572, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, or 5000 mg / kg, or any range or value derivable therein.
[0157] The quantity to be administered, both according to number of treatments and unit dose, depends on the treatment effect desired. An effective dose is understood to refer to an amount necessary to achieve a particular effect. It is contemplated that doses include doses of about 0.1, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 300, 400, 500, or 1000 pg / kg, mg / kg, pg / day, or mg / day or any range derivable therein. Furthermore, such doses can be administered at multiple times during a day, and / or on multiple days, weeks, or months.
[0158] Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the patient, the route of administration, the intended goal of treatment (alleviation of symptoms versus cure) and the potency, stability and toxicity of the particular therapeutic substance or other therapies a subject may be undergoing.
[0159] It will be understood by those skilled in the art and made aware that dosage units of pg / kg or mg / kg of body weight can be converted and expressed in comparable concentration units of pg / ml or mM (blood levels). It is also understood that uptake is species and organ / tissue dependent. The applicable conversion factors and physiological assumptions to be made concerning uptake and concentration measurement are well-known and would permit those of skill in the art to convert one concentration measurement to another and make reasonable comparisons and conclusions regarding the doses, efficacies and results described herein.- 97 -SUBSTITUTE SHEET (RULE 26)
[0160] In certain instances, it will be desirable to have multiple administrations of the composition, e.g., 2, 3, 4, 5, 6 or more administrations. The administrations can be at 1, 2, 3, 4, 5, 6, 7, 8, to 5, 6, 7, 8, 9, 10, 11, or 12 week intervals, including all ranges there between.
[0161] The phrases “pharmaceutically acceptable” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal or human. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in immunogenic and therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-infective agents and vaccines, can also be incorporated into the compositions.
[0162] The active compounds can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, subcutaneous, or intraperitoneal routes. Typically, such compositions can be prepared as either liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and, the preparations can also be emulsified.
[0163] The compositions of the present disclosure can be formulated in various forms suitable for pharmaceutical and topical delivery. Non-limiting examples include semi-solid compositions, lotions, liquid suspensions, emulsions, creams, gels, ointments, pastes, aerosol sprays, aerosol foams, non-aerosol sprays, non-aerosol foams, films, and sheets. Semi-solid compositions include ointments, pastes, and creams. For purposes of this disclosure, semi-solid compositions are not sprayable. The compositions can be impregnated in gauzes, bandages, or other skin dressing materials. In some aspects, the compositions are semi-solid compositions. In some aspects, the compositions are ointments. In other aspects, the compositions are gels. In still other aspects, the compositions are liquid suspensions. In some aspects, the compositions are not sprays and are not spray able.
[0164] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including, for example, aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
[0165] A pharmaceutical composition can include a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid- 98 -SUBSTITUTE SHEET (RULE 26)polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various anti-bacterial and anti-fungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0166] Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization or an equivalent procedure. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques, which yield a powder of the active ingredient, plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[0167] Administration of the compositions will typically be via any common route. This includes, but is not limited to oral, or intravenous administration. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, or intranasal administration. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients.
[0168] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above.A. Cancer Therapy
[0169] In some aspects, the disclosed methods comprise administering a cancer therapy to a subject or patient. In some aspects, one or more of the DNA-binding dimers comprise the cancer therapy. In some aspects, the cancer therapy comprises the DNA-binding dimer and optionally another composition used to treat cancer. The cancer therapy may be chosen based on an expression level measurements, alone or in combination with the clinical risk score calculated for the subject. The cancer therapy may be chosen based on a genotype of a subject. The cancer- 99 -SUBSTITUTE SHEET (RULE 26)therapy may be chosen based on the presence or absence of one or more polymorphisms in a subject. In some aspects, the cancer therapy comprises a local cancer therapy. In some aspects, the cancer therapy excludes a systemic cancer therapy. In some aspects, the cancer therapy excludes a local therapy. In some aspects, the cancer therapy comprises a local cancer therapy without the administration of a system cancer therapy. In some aspects, the cancer therapy comprises administration of a bZIP transcriptional repressor of the present disclosure. In some aspects, the cancer therapy comprises chemotherapy. In some aspects, the cancer therapy comprises radiotherapy. In some aspects, the cancer therapy comprises surgery. In some aspects, the cancer therapy comprises an immunotherapy, which may be a checkpoint inhibitor therapy. Any of these cancer therapies may also be excluded. Combinations of these therapies may also be administered.
[0170] The term “cancer,” as used herein, may be used to describe a solid tumor, metastatic cancer, or non-metastatic cancer. In certain aspects, the cancer may originate in the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, duodenum, small intestine, large intestine, colon, rectum, anus, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus. In some aspects, the cancer is a Stage I cancer. In some aspects, the cancer is a Stage II cancer. In some aspects, the cancer is a Stage III cancer. In some aspects, the cancer is a Stage IV cancer.
[0171] The cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; paget’s disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w / squamous- 100 -SUBSTITUTE SHEET (RULE 26)metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; androblastoma, malignant; sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extra-mammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi’s sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; hodgkin’s disease; hodgkin’s; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-hodgkin’s lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia.
[0172] In some aspects, the cancer is breast cancer. In some aspects, the cancer is triple negative breast cancer. For example, where the cancer is triple negative breast cancer, a therapeutic method may comprise administration of an engineered DNA-binding dimer capable of competing for DNA binding with a HIF protein (e.g., HIFla and / or XBP1).
[0173] Methods may involve the determination, administration, or selection of an appropriate cancer “management regimen” and predicting the outcome of the same. As used herein the phrase “management regimen” refers to a management plan that specifies the type of examination,- 101 -SUBSTITUTE SHEET (RULE 26)screening, diagnosis, surveillance, care, and treatment (such as dosage, schedule and / or duration of a treatment) provided to a subject in need thereof (e.g., a subject diagnosed with cancer).B. Fibrotic Disorder Therapy
[0174] In some aspects, the disclosed methods comprise administering a therapy for treating a fibrotic disorder. Fibrotic disorders contemplated herein include, but are not limited to, liver fibrosis, renal fibrosis, cardiac fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), scleroderma, psoriasis, and myelofibrosis. The present disclosure includes methods for treatment of a fibrotic disorder comprising administering to a subject an effective amount of a bZIP transcriptional repressor of the present disclosure. A bZIP transcriptional repressor of the disclosure may be used in combination with the administration of conventional therapies for fibrotic disorders, such as those known in the art.C. Diabetes Therapy
[0175] In some aspects, the disclosed methods comprise administering a therapy for treating diabetes. In some aspects, the diabetes is type 1 diabetes. In some aspects, the diabetes is type 2 diabetes. The present disclosure includes methods for treatment of diabetes comprising administering to a subject an effective amount of a bZIP transcriptional repressor of the present disclosure. A bZIP transcriptional repressor of the disclosure may be used in combination with the administration of conventional therapies, such as those known in the art and / or described below. For example, the current methods and compositions may be used in combination with traditional therapies for treating diabetes. Traditional therapies for diabetes include metformin, sulfonylureas, such as glyburide, glipizide, and glimepiride (Amaryl), meglitinides such as repaglinide and nateglinide, thiazolidinediones such as rosiglitazone and pioglitazone, DPP-4 inhibitors such as sitagliptin, saxagliptin, and linagliptin, GLP-1 receptor agonists such as exenatide and liraglutide, SGLT2 inhibitors such as canagliflozin and dapagliflozin, insulin therapy such insulin glulisine, insulin lispro, insulin aspart, insulin glargine, insulin detemir, and insulin isophane, and aspirin therapy.D. Pharmaceutical Compositions
[0176] In certain aspects, the nanoparticle compositions, including those comprising engineered DNA-binding dimers, are suitably contained in a pharmaceutically acceptable carrier. The carrier is non-toxic, biocompatible and is selected so as not to detrimentally affect the biological activity of the agent. The agents in some aspects of the disclosure may be formulated into preparations for local delivery or systemic delivery, in solid, semi-solid, gel, liquid or gaseous - 102 -SUBSTITUTE SHEET (RULE 26)forms such as tablets, capsules, powders, granules, ointments, solutions, depositories, inhalants and injections allowing for oral, parenteral or surgical administration. Certain aspects of the disclosure also contemplate local administration of the compositions by coating medical devices and the like.
[0177] Suitable carriers for parenteral delivery via injectable, infusion or irrigation and topical delivery include distilled water, physiological phosphate-buffered saline, normal or lactated Ringer's solutions, dextrose solution, Hank's solution, or propanediol. In addition, sterile, fixed oils may be employed as a solvent or suspending medium. For this purpose any biocompatible oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. The carrier and agent may be compounded as a liquid, suspension, polymerizable or non-polymerizable gel, paste or salve.
[0178] In certain aspects, the actual dosage amount of a composition administered to a patient or subject can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
[0179] Solutions of pharmaceutical compositions can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[0180] In certain aspects, the pharmaceutical compositions are advantageously administered in the form of injectable compositions either as liquid solutions or suspensions; solid forms suitable or solution in, or suspension in, liquid prior to injection may also be prepared. These preparations also may be emulsified. A typical composition for such purpose comprises a pharmaceutically acceptable carrier. For instance, the composition may contain 10 mg or less, 25 mg, 50 mg or up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like.
[0181] Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic / aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial agents, antgifungal agents, anti-oxidants, chelating agents and inert gases. The pH- 103 -SUBSTITUTE SHEET (RULE 26)and exact concentration of the various components the pharmaceutical composition are adjusted according to well-known parameters.
[0182] Additional formulations are suitable for oral administration. Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. The compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
[0183] In further aspects, the pharmaceutical compositions may include classic pharmaceutical preparations. Administration of pharmaceutical compositions according to certain aspects may be via any common route so long as the target tissue is available via that route. This may include oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients. For treatment of conditions of the lungs, aerosol delivery can be used. Volume of the aerosol may be between about 0.01 ml and 0.5 ml, for example.
[0184] An effective amount of the pharmaceutical composition is determined based on the intended goal. The term “unit dose” or “dosage” refers to physically discrete units suitable for use in a subject, each unit containing a predetermined-quantity of the pharmaceutical composition calculated to produce the desired responses discussed above in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the protection or effect desired.
[0185] Precise amounts of the pharmaceutical composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting the dose include the physical and clinical state of the patient, the route of administration, the intended goal of treatment (e.g., alleviation of symptoms versus cure) and the potency, stability and toxicity of the particular therapeutic substance.Examples
[0186] The following examples are included to demonstrate certain aspects of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute certain modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can- 104 -SUBSTITUTE SHEET (RULE 26)be made in the specific aspects which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.Example 1 - Design Pipeline for Generation of Synthetic DNA Binding Dimers
[0187] A DNA binding dimer is designed starting from natural bZIP proteins. First, amino acid sequences for first and second natural bZIP proteins are obtained from a sequence database (e.g., UniProt). For a heterodimer, the first and second proteins are different proteins. For a homodimer, the first and second proteins are the same protein. An example natural sequence for each of a first and second natural bZIP protein is provided below. c-Fos (Homo sapiens):MMF SGFNAD YEAS S SRC S S ASP AGD SLS YYHSP AD SF S SMGSP VNAQDFCTDL AVS SAN FIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGR AQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSA LQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAF TLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYA ADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHR KGSSSNEPSSDSLSSPTLLAL (SEQ ID NO:3) c-Jun (Homo sapiens):MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSD LLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTFLCPKNVTDEQEGFAEGFVRALAELH SQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGA LSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGE TPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTA NMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF (SEQ ID NO: 6)
[0188] Second, the basic domain and leucine zipper domain of the first and second proteins are identified. The leucine zipper domain is identified based on the repetitive leucines every seven residues, plus three more residues toward the N-terminus from the first leucine. The basic domain is identified as the 26 residues immediately N-terminal of the first residue of the leucine zipper domain. Example sequences comprising the basic domain and leucine zipper domain are shown below. c-Fos (Homo sapiens) basic domain and leucine zipper domain:MKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFI LAAH (SEQ ID NO: 104) c-Jun (Homo sapiens) basic domain and leucine zipper domain:- 105 -SUBSTITUTE SHEET (RULE 26)ERIKAEKRKMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQL KQKVMN (SEQ ID NO : 105)
[0189] Third, the minimum necessary DNA recognition sequence of the first and second proteins is determined. The minimum necessary DNA recognition sequence is identified as the first 21 residues at the C-terminal end of the basic domain and the first 12 residues of the leucine zipper domain. Example minimum necessary DNA recognition sequences are provided below. c-Fos (Homo sapiens) minimum necessary DNA recognition sequence:IRRERNKMAAAKCRNRRRELTDTLQAETDQLE (SEQ ID NO: 106) c-Jun (Homo sapiens) minimum necessary DNA recognition sequence: IRRERNKMAAAKCRNRRRELTDTLQAETDQLE (SEQ ID NO: 107)
[0190] Fourth, all cysteines in the minimum necessary DNA recognition sequences of the first and second proteins are mutated based on the following rules:If a cysteine is in the basic domain, replace it with a serineIf a cysteine is at a b, c, or f position of the leucine zipper domain, replace it with an alanine If a cysteine is at an a or d position of the leucine zipper domain, replace it with a leucine.
[0191] Fifth, the linker position on each protein is identified. The linker position on the first protein is identified as the last residue of the basic domain. The linker position on the second protein is identified as the first residue at an e position of the leucine zipper domain. The linker residue on the first protein is replaced with a cysteine and the linker residue on the second protein is replaced with a Lys(mmt).
[0192] Sixth, weaker interhelix contact residues on the first and second proteins are replaced with stronger residues based on the following rules:If a residue at an a or d position of a leucine zipper domain is neither a leucine nor an isoleucine, replace it with a leucine.If a residue at a gi position of the first protein and a paired residue at an ei+i position of the second protein are not either KE, EK, RE, ER, or QQ, replace the positions so that they are KE or RE (where the first letter indicates the residue at the gi position of the first protein and the second letter indicates the ei+1 position of the second protein).
[0193] Seventh, intrapeptide stabilizing linkage positions are identified for the first and second proteins. Intrapeptide stabilizing linkage positions are identified as either:1) the fourth residue and the eighth residue of the minimum necessary DNA recognition sequence; or2) the 22ndresidue and the 26thresidue of the minimum necessary DNA recognition sequence.- 106 -SUBSTITUTE SHEET (RULE 26)Example 2 - Developing Dual STR / STING-NCP Formulations for In Vivo Delivery.
[0194] A procedure for STR encapsulation in NCP-nanoparticle was performed as follows. First, co-polymerization of Zn2+ions with l,2-dioleoyl-sn-glycero-3 -phosphate (DOPA) in a reverse microemulsion results in a Zn bare core. The zinc bare core was then coated with STR22, cholesterol, l,2-dioleoyl-sn-glycero-3 -phosphocholine (DOPC), and 1,2-diastearoyl-sn-glycero- 3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (DSPE-PEG2000) to afford coreshell STR22 NCP complex. Finalized STR22-NCP complexes were stored in PBS at 4 degree C.
[0195] To validate STR22 loading and stability in NCP nanoparticles, the STR22-NCP formulation was first spun down at 20,000x g for 10 min. Supernatant was saved for the LCMS analysis. STR22-NCP was separated as the pellet and then re-dissolved in the 95% TFA and 5% water. OX / STR22 NCP dissociated in TFA mix. STR22 solution was then diluted 500 times in water for LCMS analysis. STR22 was prepared in different concentration in water to build a standard curve. Ion intensity from MS was used as the readout. Both STR+ NCP diluted sample and supernatant sample were subjected to LCMS test. LCMS showed a >90% loading efficiency of STR22 NCP complex (FIG. 21). This method of loading and nanoparticle-STR delivery is general to all STRs of different classes and compositions.
[0196] 10 mg / mL STR22-NCP complex was used in pharmacokinetic (PK), pharmacodynamic, and efficacy studies. The concentration of STR22 was based on the initial amount of STR22 used to compose the complex given the loading efficiency is above 90%. For PK study, 100 or 50 pL of 10 mg / mL STR22-NCP or 100 or 50 pL of 2 mg / mL STR22-NCP (diluted from 10 mg / mL STR22- NCP in PBS) was injected through tail vein to the mouse with the weight of each mouse assumed to be 20 g to achieve the dose: 50, 25, 10, 5 mg / kg. The blood was then collected through submandibular collection method. ~50 pL of blood was collected for each time point. Blood was then first centrifuged at 4 °C, lOOOx g for 10 minutes and then diluted with lOx volume of 2% formic acid and then further diluted with 4x volume (based on volume of diluted sample) of methanol and then finally centrifuged at 17,000x g for 3 minutes to prepare the sample for LCMS detection. The standard curve was generated by LCMS analysis of a serial of different concentration of STR22 in serum which underwent the same protocol as blood sample. Ion intensity from MS was used as the readout. Serum concentration was calculated using standard curve (FIG. 22). Pharmacokinetic analysis using LCMS established that intravenous STR-NCP from 50 to 5 mg / kg had an effective blood retention with the half-life of between approximately 6-8 hrs.
[0197] IV dosing used for efficacy studies are as follows. LC-MS method utilized to quantify STR concentrations in serum. PD studies established a prolonged effect (-24-72 hr) on target expression following single doses of STR22 in tumors (FIG. 23). STR22 was used for in vivo- 107 -SUBSTITUTE SHEET (RULE 26)studies for class of STR-NCP complex (PK, tolerability, PD, efficacy); studies using STR116 (which can target MYC) was also tested in a similar manner for a STR-NCP complex. Other STR- NCP complexes using synthetic transcriptional repressors targeting these protein targets and other proteins will be tested. As with STR22, IV delivery of STR116 in a STR-NCP complex up to 50 mg / kg shows no signs of tox / weight loss in healthy mice. Tolerability is also monitored in expanded efficacy studies with different tumor models.
[0198] Fluorophore-labeled STR22 used in aNCP-STR22 complex was injected intravenously at 50 mg / kg. Tumors were excised at given time points and imaged for STR22 uptake and distribution kinetics in Balb / c mice. Tumor uptake observed in 4-24 hour period following primary AUC from IV delivery showed accumulation in a 4T1 breast cancer tumor model (FIG. 24).
[0199] To further characterize the pharmacodynamics of STR22-NCP formulations, 8-10 week-old female BALB / c mice were seeded with 2xl064T1 cells in their fourth fat mammary pad. After four weeks, the tumors reached 400-500 mm3(by caliber measurement). The mice were then sorted to be of the similar size between vehicle group (Free NCP without any STR loaded as vehicle) and STR-NCP group. The mice were then injected with either free NCP or 50 mg / kg STR- NCP through tail vein and sacrificed two days after the injection. The tumors were then collected and mRNA were extracted from the tumors and further analyzed by qPCR. VEGFA and GLUT1 were used as validation genes regulated by HIFla. The mRNA level of VEGFA and GLUT1 were first normalized to RPL13A, a ribosomal RNA that served as the internal control, and then normalized to vehicle. One single injection of 50 mg / kg STR / NCP through IV on BALB / c mice bearing 4T1 tumors shows that STR / NCP block the HIF1 downstream gene expression at 48 hrs (FIG. 25). Further, 24, 48, and 72 hr timepoint measurements were collected and GLUT1 levels were analyzed (FIG. 26) showing continued reduction of GLUTE
[0200] Next, pharmacodynamic analysis of a multiple dosing schedule was performed (FIG. 27A) using 8-10 week-old female BALB / c mice seeded with 2xl064T1 cells in their fourth fat mammary pad. The dosing schedule was an single injection every three days. Both tumor volume and mouse body weight were monitored. Administering 50 mg / kg STR / NCP intravenously to BALB / c mice bearing 4T1 tumors demonstrated no apparent toxicity or body weight loss in the efficacy study (FIG. 27B).
[0201] Next, the efficacy of the multiple dosing schedule of STR22-NCP formulations was analyzed using 8-10 week-old female BALB / c mice seeded with 2xl064T1 cells in their fourth fat mammary pad. Free NCP (vehicle) or 50 mg / kg STR22+ NCP were administered intravenously when the average tumor size reached 50 mm3(caliber measurement). Dosing schedule was one injection every three days. Tumor volume was measured during the treatment (FIG. 28 A). The treatment was continued until the average vehicle-treated tumor size reached 700-800 mm3. Mice- 108 -SUBSTITUTE SHEET (RULE 26)were taken down and tumors and lungs were collected. Tumors were subjected to mRNA-qPCR analysis on the classical HIF la-regulated genes and lungs were fixed with 70% ethanol and analyzed by necroscopy. Number of total lung cells and tumor cells were then quantified by qupath. Long-term repetitive treatment of 50 mg / kg STR / NCP through IV on BALB / c mice bearing 4T1 tumors shows that STR / NCP inhibits 4T1 tumor growth and metastases (FIGs. 28A- 28B).
[0202] The tolerability of the STR22-NCP formulations were also analyzed. IP, subcutaneous, and IV delivery of STR22-NCP at doses of 5, 10, and 35 mg / kg showed no acute toxicity (FIGs. 29A-29C). Longer term tracking showed no apparent toxicity or body weight loss across IP or IV dose ranges. No significant weight loss observed in efficacy studies (FIG. 29D).
[0203] STR22-NCP nanoparticle formulation provides proof of concept for development of other STR nanoparticles for in vivo delivery. The high loading efficiency of STR into NCP indicates the potential use on other potential delivery methods. The inventors will use polymersome, dendrimer, metal-organic framework (MOF), silica nanoparticle, liposome, lipid nanoparticle, gold nanoparticles, polymer micelles, and / or nanospheres to load the STR compositions.
[0204] Building off of these preliminary studies the inventors will test the formulation and release efficacy of dual-encapsulated STR / STING-NCP nanoparticles. Release kinetics and on- target efficacy will be confirmed in GMB cell lines. Additionally, in vivo tolerability, pharmacokinetics and pharmacodynamics will correlate with established NCP-STR and NCP- STING agonist nanoparticles to ensure delivery across the BBB.
[0205] The inventors will test whether delivery of NCP-STRs to GBMs result in inhibition of hypoxia-dependent signaling and immunosuppressive tumor microenvironment hallmarks. Using orthotopic and genetically engineered models of GBM, the inventors perform dose- and time- resolved systemic delivery studies of lead STR-NCPs (via IV injection) followed by tumor resection and analysis of HIF la target gene expression, hypoxic and angiogenic marker expression, and immune infiltration into tumors. These data support the potential to counteract HIF 1 -dependent immunosuppression with STRs, which is shown through causal links between hypoxia and immunosuppressive microenvironments.
[0206] The inventors test whether the dual-loaded STR / STING-NCP nanoparticles demonstrate efficacy in orthotopic mouse models of GBM. The inventors employ GL261 tumors generated by stereotactic injection, which has been used to explore STING activation and efficacy. These efficacy studies are guided by these previous trials with NCP loaded STING agonists as well as pharmacodynamic studies described herein. Multiple efficacy endpoints are considered, including effect on tumor burden, survival and histopathological measures of tumor hypoxia and- 109 -SUBSTITUTE SHEET (RULE 26)an immunosuppressive microenvironment. These studies can translate to clinical strategies for treating GBM and other cancers.* * *
[0207] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of certain aspects, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.- 110 -SUBSTITUTE SHEET (RULE 26)
Claims
CLAIMS1. A nanoparticle composition comprising at least one nanoparticle, the composition comprising at least one engineered DNA-binding dimer comprising:(a) a first engineered peptide comprising (i) a modified basic domain sequence of a first bZIP protein and (ii) a modified leucine zipper domain sequence of the first bZIP protein; and,(b) a second engineered peptide linked to the first engineered peptide via a side-by- side interpeptide linkage, the second engineered peptide comprising (i) a modified basic domain sequence of a second bZIP protein and (ii) a modified leucine zipper domain sequence of the second bZIP protein, wherein each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “a” of their respective leucine zipper domain sequences, or wherein each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “d” of their respective leucine zipper domain sequences.
2. The nanoparticle composition of claim 1, wherein each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “a” of their respective leucine zipper domain sequences.
3. The nanoparticle composition of claim 2, wherein each of the first and second bZIP proteins, individually, have an isoleucine, leucine, or valine at position “d” of their respective leucine zipper domain sequences.
4. The nanoparticle composition of any one of claims 1 to 3, wherein each of the first and second bZIP proteins, individually, have a leucine at position “a” of their respective leucine zipper domain sequences.
5. The nanoparticle composition of any one of claims 1 to 3, wherein each of the first and second bZIP proteins, individually, have an isoleucine at position “a” of their respective leucine zipper domain sequences.
6. The nanoparticle composition of any one of claims 1 to 5, wherein each of the first and second bZIP proteins, individually, have a leucine at position “d” of their respective leucine zipper domain sequences.- I l l -SUBSTITUTE SHEET (RULE 26)7. The nanoparticle composition of any one of claims 1 to 5, wherein each of the first and second bZIP proteins, individually, have an isoleucine at position “d” of their respective leucine zipper domain sequences.
8. The nanoparticle composition of any one of claims 1 to 7, wherein: a glutamine is present at position “e” of the leucine zipper domain sequence of the first bZIP protein and a glutamine is present at position “g” of the leucine zipper domain sequence of the second bZIP protein; or an arginine is present at position “e” of the leucine zipper domain sequence of the first bZIP protein and a glutamic acid is present at position “g” of the leucine zipper domain sequence of the second bZIP protein.
9. The nanoparticle composition of any one of claims 1 to 7, wherein: an arginine is present at position “e” of the leucine zipper domain sequence of the second bZIP protein and a glutamic acid is present at position “g” of the leucine zipper domain sequence of the first bZIP protein.
10. The nanoparticle composition of any one of claims 1 to 9, wherein at least one or both of the leucine zipper domain sequences of the first and / or second bZIP proteins have an alanine at least at one or more of positions “b”, “c”, or “f”.
11. The nanoparticle composition of any one of claims 1 to 10, wherein the modified basic domain sequence of the first bZIP protein is at most 25 residues in length.
12. The nanoparticle composition of claim 11, wherein the modified basic domain sequence of the first bZIP protein is 20 residues in length.
13. The nanoparticle composition of claim 1, wherein the modified leucine zipper domain sequence of the first bZIP protein is at most 15 residues in length.
14. The nanoparticle composition of claim 13, wherein the modified leucine zipper domain sequence of the first bZIP protein is 12 residues in length.
15. The nanoparticle composition of any of claims 1-14, wherein the first engineered peptide is at most 40 residues in length.- 112 -SUBSTITUTE SHEET (RULE 26)16. The nanoparticle composition of claim 15, wherein the first engineered peptide is 32 residues in length.
17. The nanoparticle composition of any of claims 1-16, wherein the modified basic domain sequence of the second bZIP protein is at most 25 residues in length.
18. The nanoparticle composition of claim 17, wherein the modified basic domain sequence of the second bZIP protein is 20 residues in length.
19. The nanoparticle composition of any of claims 1-18, wherein the modified leucine zipper domain sequence of the second bZIP protein is at most 15 residues in length.
20. The nanoparticle composition of claim 19, wherein the modified leucine zipper domain sequence of the second bZIP protein is 12 residues in length.
21. The nanoparticle composition of any of claims 1-20, wherein the second engineered peptide is at most 40 residues in length.
22. The nanoparticle composition of claim 21, wherein the second engineered peptide is 32 residues in length.
23. The nanoparticle composition of any of claims 1-22, wherein the modified basic domain sequence of the first bZIP protein comprises a serine substituted for any cysteine relative to a native basic domain sequence of the first bZIP protein.
24. The nanoparticle composition of any of claims 1-23, wherein the modified basic domain sequence of the second bZIP protein comprises a serine substituted for any cysteine relative to a native basic domain sequence of the second bZIP protein.
25. The nanoparticle composition of any of claims 1-24, wherein the modified leucine zipper domain sequence of the first bZIP protein comprises an alanine substituted for any cysteine at a “b”, “c”, or “f ’ position relative to a native leucine zipper domain sequence of the first bZIP protein.
26. The nanoparticle composition of any of claims 1-25, wherein the modified leucine zipper domain sequence of the first bZIP protein comprises a leucine substituted for any cysteine at an “a” or “d” position relative to a native leucine zipper domain sequence of the first bZIP protein.- 113 -SUBSTITUTE SHEET (RULE 26)27. The nanoparticle composition of any of claims 1-26, wherein the modified leucine zipper domain sequence of the second bZIP protein comprises an alanine substituted for any cysteine at a “b”, “c”, or “f ’ position relative to a native leucine zipper domain sequence of the second bZIP protein.
28. The nanoparticle composition of any of claims 1-27, wherein the modified leucine zipper domain sequence of the second bZIP protein comprises a leucine substituted for any cysteine at an “a” or “d” position relative to a native leucine zipper domain sequence of the second bZIP protein.
29. The nanoparticle composition of any of claims 1-28, wherein the modified basic domain sequence of the first bZIP protein comprises a cysteine at a position corresponding to the last position of a native basic domain sequence of the first bZIP protein.
30. The nanoparticle composition of claim 29, wherein the cysteine is a natural cysteine.
31. The nanoparticle composition of claim 29, wherein the cysteine is a modified cysteine.
32. The nanoparticle composition of any of claims 1-31, wherein the modified leucine zipper domain sequence of the second bZIP protein comprises a lysine at a position corresponding to a first “e” position of a native leucine zipper domain sequence of the second bZIP protein.
33. The nanoparticle composition of any of claims 29-32, wherein the side-by-side interpeptide linkage is between the cysteine and the lysine.
34. The nanoparticle composition of any of claims 1-33, wherein the modified leucine zipper domain sequence of the first bZIP protein comprises a leucine in place of any residue at an “a” or “d” position that is not a leucine or isoleucine relative to a native leucine zipper domain of the first bZIP protein.
35. The nanoparticle composition of any of claims 1-34, wherein the modified leucine zipper domain sequence of the second bZIP protein comprises a leucine in place of any residue at an “a” or “d” position that is not a leucine or isoleucine relative to a native leucine zipper domain of the second bZIP protein.
36. The nanoparticle composition of any of claims 1-35, wherein the first and second bZIP proteins, individually, comprise one or more intrapeptide stabilizing linkages, wherein the intrapeptide stabilizing linkage(s) crosslinks two amino acids in an amino acid pair.- 114 -SUBSTITUTE SHEET (RULE 26)37. The nanoparticle composition of claim 36, wherein each amino acid of the amino acid pair is within an alpha helical segment of the first bZIP protein.
38. The nanoparticle composition of claim 36 or 37, wherein each amino acid of the amino acid pair is within an alpha helical segment of the second bZIP protein.
39. The nanoparticle composition of claim 37 or 38, wherein the two amino acids in the amino acid pair are at position i and i+4.
40. The nanoparticle composition of any of claims 37-39, wherein the two amino acids in the amino acid pair are at position i and i+7.
41. The nanoparticle composition of any of claims 37-40, wherein the hydrocarbon intrapeptide stabilizing linkage comprises an optionally substituted alkyl chain or an optionally substituted alkenyl chain stapling a pair of amino acids on the first or second bZIP protein.
42. The nanoparticle composition of ay one of claims 37-40, wherein the amino acids in the amino acid pair comprise S-2-(4'-pentenyl) alanine and / or R-2-(7 '-octenyl) alanine.
43. The nanoparticle composition of any of claims 1-41, wherein the first and second bZIP protein comrpise an interpeptide linkage.
44. The nanoparticle composition of claim 43, wherein the interpeptide linkage is between non-terminal amino acids of the first and second bZIP protein.
45. The nanoparticle composition of claim 43 or 44, wherein the interpeptide linkage is between amino acids in a basic region of the first and second bZIP proteins.
46. The nanoparticle composition of any of claims 43-45, wherein the interpeptide linkage comprises maleamide.
47. The nanoparticle composition of any of claims 1-46, wherein the first bZIP protein is c- Fos.
48. The nanoparticle composition of claim 47, wherein the modified DNA-binding domain sequence of c-Fos comprises:IRRERNKMAAAKSRNRRREC (SEQ ID NO: 16);- 115 -SUBSTITUTE SHEET (RULE 26)IRR#RNK#AAAKSRNRRREC (SEQ ID NO: 17);EEKRRIRRERNKMAAAKSRNRRREC (SEQ ID NO: 18); orEEKRRIRR#RNK#AAAKSRNRRREC (SEQ ID NO: 19); wherein # are intrapeptide stabilizing linkage sites which together form the structure49. The nanoparticle composition of claim 47 or 48, wherein the modified leucine zipper domain sequence of c-Fos comprises:TDTLEDETDQLE (SEQ ID NO20);LDELQAEIEQLE (SEQ ID NO:21);IDELQAEIEQLE (SEQ ID NO:22);IDEIQAEIEQIE (SEQ ID NO:23);L#ELQ#EIEQLE (SEQ ID NO:24);I#ELQ#EIEQLE (SEQ ID NO:25); orI#EIQ#EIEQIE (SEQ ID NO:26); wherein # are intrapeptide stabilizing linkage sites which together form the structure50. The nanoparticle composition of any of claims 1-49, wherein the second bZIP protein is c-Jun.
51. The nanoparticle composition of claim 50, wherein the modified DNA-binding domain sequence of c-Jun is:RKRMRNRIAASKSRKRKLER (SEQ ID NO:27);- 116 -SUBSTITUTE SHEET (RULE 26)RKR#RNR#AASKSRKRKLER (SEQ ID NO:28);RIKAERKRMRNRIAASKSRKRKLER (SEQ ID NO:29); orRIKAERKR#RNR#AASKSRKRKLER (SEQ ID NO: 30); wherein # are intrapeptide stabilizing linkage sites which together form the structure52. The nanoparticle composition of claim 50 or 51, wherein the modified leucine zipper domain sequence of c-Jun comprises: lAKmLEEKVKTLK (SEQ ID NO: 31); lARLKmEKVKTLK (SEQ ID NO:32);AAELKmEKVATLK (SEQ ID NO:33); lARLKmEKIKTLK (SEQ ID NO:34); lARIKmEKIKTIK (SEQ ID NO: 35);I#RLKm#KVKTLK (SEQ ID NO: 36); orI#RLKm#KIKTLK (SEQ ID NO: 37); wherein# are intrapeptide stabilizing linkage sites which together form the structureKm is is a Lys residue attached to a maleimide-linker forming a portion of the- 117 -SUBSTITUTE SHEET (RULE 26)53. The nanoparticle composition of any of claims 1-35, wherein the first bZIP protein is XBP1.
54. The nanoparticle composition of claim 53, wherein the modified DNA-binding domain sequence of XBP1 comprises:RRKLKNRVAAQTARDRKKAC (SEQ ID NO: 38); orRRK#KNR#AAQTARDRKKAC (SEQ ID NO: 39); wherein # are intrapeptide stabilizing linkage sites which together form the structure55. The nanoparticle composition of claim 53 or 54, wherein the modified leucine zipper domain sequence of XBP1 comprises:MSELEQQVVDLE (SEQ ID NO:40);LSELEQQVVDLE (SEQ ID NO:41); orL#ELE#QVVDLE (SEQ ID NO:42); wherein # are intrapeptide stabilizing linkage sites which together form the structure- 118 -SUBSTITUTE SHEET (RULE 26)56. The nanoparticle composition of any of claims 53-55, wherein the second bZIP protein is XBP1.
57. The nanoparticle composition of any of claim 56, wherein the modified DNA-binding domain sequence of XBP1 comprises:RRKLKNRVAAQTARDRKKAR (SEQ ID NO:43); orRRK#KNR#AAQTARDRKKAR (SEQ ID NO:44); wherein # are intrapeptide stabilizing linkage sites which together form the structure58. The nanoparticle composition of any of claim 56 or 57, wherein the modified leucine zipper domain sequence of XBP1 comprises:MSELKmQQVVDLE (SEQ ID NO:45);LSELKmQQVVDLE (SEQ ID NO:46); orL#ELKm#QVVDLE (SEQ ID NO:47); wherein# are intrapeptide stabilizing linkage sites which together form the structureKm is a Lys residue attached to a maleimide-linker forming a portion of the structure:- 119 -SUBSTITUTE SHEET (RULE 26)59. The nanoparticle composition of any of claims 1-35, wherein the first bZIP protein is ATF4.
60. The nanoparticle composition of claim 59, wherein the modified DNA-binding domain sequence of ATF4 comprises:KKMEQNKTAATRYRQKKRAC (SEQ ID NO:48); wherein # are intrapeptide stabilizing linkage sites which together form the structure61. The nanoparticle composition of any claim 59 or 60, wherein the modified leucine zipper domain sequence of ATF4 comprises:QEALTGELKELE (SEQ ID NO:49);LEALKAELKELR (SEQ ID NO:50); orL#ALK#ELKELR (SEQ ID NO:51).
62. The nanoparticle composition of any of claims 1-35, wherein the first bZIP protein is C / EBPp.
63. The nanoparticle composition of claim 62, wherein the modified DNA-binding domain sequence of C / EBPp comprises:IRRERNNIAVRKSRDKAKMC (SEQ ID NO:52);- 120 -SUBSTITUTE SHEET (RULE 26)wherein # are intrapeptide stabilizing linkage sites which together form the structure64. The nanoparticle composition of claim 62 or 63, wherein the modified leucine zipper domain sequence of CZEBPp comprises:LLELQHKVLELR (SEQ ID NO:53); orL#ELQ#KVLELR (SEQ ID NO: 54); wherein # are intrapeptide stabilizing linkage sites which together form the structure65. The nanoparticle composition of any of claims 59-64, wherein the second bZIP protein is ATF4.
66. The nanoparticle composition of claim 65, wherein the modified DNA-binding domain sequence of ATF4 comprises:KKMEQNKTAATRYRQKKRAE (SEQ ID NO: 55); wherein # are intrapeptide stabilizing linkage sites which together form the structure67. The nanoparticle composition of claim 65 or 66, wherein the modified leucine zipper domain sequence of ATF4 comprises:QEALKmGELKELE (SEQ ID NO:56);LEALKmAELKELR (SEQ ID NO: 57); orL#ALKm#ELKELR (SEQ ID NO: 58);SUBSTITUTE SHEET (RULE 26)wherein# are intrapeptide stabilizing linkage sites which together form the structureKm is a Lys residue attached to a maleimide-linker forming a portion of the68. The nanoparticle composition of any of claims 1-67, wherein the first engineered peptide comprises a intrapeptide stabilizing linkage.
69. The nanoparticle composition of claim 68, wherein the intrapeptide stabilizing linkage is between the fourth position and the eighth position of the first engineered peptide.
70. The nanoparticle composition of claim 68, wherein the intrapeptide stabilizing linkage is between the twenty-second position and the twenty-sixth position of the first engineered peptide.
71. The nanoparticle composition of any of claims 1-68, wherein the second engineered peptide comprises a intrapeptide stabilizing linkage.
72. The nanoparticle composition of claim 71, wherein the intrapeptide stabilizing linkage is between the fourth position and the eighth position of the second engineered peptide.- 122 -SUBSTITUTE SHEET (RULE 26)73. The nanoparticle composition of claim 71, wherein the intrapeptide stabilizing linkage is between the twenty-second position and the twenty-sixth position of the second engineered peptide.
74. The nanoparticle composition of any of claims 1-73, wherein the side-by-side interpeptide linkage comprises a maleimide-thiol adduct.
75. The nanoparticle composition of claim 74, wherein the side-by-side interpeptide linkage76. The nanoparticle composition of any one of claims 1-75, wherein the nanoparticle comprises nanoscale coordination polymers.
77. The nanoparticle composition of any one of claims 1-76, wherein the nanoparticle comprises l,2-dioleoyl-sn-glycero-3-phosphate (DOPA).
78. The nanoparticle composition of any one of claims 1-77, wherein the nanoparticle comprises l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
79. The nanoparticle composition of any one of claims 1-78, wherein the nanoparticle comprises l,2-diastearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (DSPE-PEG2000).
80. The nanoparticle composition of any one of claims 1-79, wherein the nanoparticle comprises zinc.
81. The nanoparticle composition of any one of claims 1-80, wherein the nanoparticle comprises cholesterol.
82. The nanoparticle composition of any one of claims 1-81, wherein the nanoparticle comprises solid lipid nanoparticles, liposomes, niosomes, ethosomes, electrostatic particulates, microemulsions, nanoemulsions, microsuspensions, nanosuspensions, multilamellar nanoparticle vesicles, unilamellar nanoparticle vesicles, multivesicular nanoparticles, emulsion particles, irregular particles with lamellar structures and bridges, partial emulsion particles, combined lamellar and emulsion particles, or combinations thereof.- 123 -SUBSTITUTE SHEET (RULE 26)83. The nanoparticle composition of any one of claims 1-81, wherein the nanoparticle comprises an oil-in-water emulsion, water-in-oil emulsion, water-in-oil-in-water emulsion, oil-in-water-in-oil emulsion, liposome, solid lipid particles formulation, or combination thereof.
84. The nanoparticle of any one of claims 1-83, wherein the nanoparticle comprises an outer layer and an inner layer.
85. The nanoparticle composition of claim 84, wherein the DNA-binding dimer is between the outer layer and inner layer.- 124 -SUBSTITUTE SHEET (RULE 26)6. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 125 -SUBSTITUTE SHEET (RULE 26)7. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 126 -SUBSTITUTE SHEET (RULE 26)8. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 127 -SUBSTITUTE SHEET (RULE 26)9. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 128 -SUBSTITUTE SHEET (RULE 26)0. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 129 -SUBSTITUTE SHEET (RULE 26)1. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 130 -SUBSTITUTE SHEET (RULE 26)92. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:SUBSTITUTE SHEET (RULE 26)3. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 132 -SUBSTITUTE SHEET (RULE 26)94. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:SUBSTITUTE SHEET (RULE 26)5. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 134 -SUBSTITUTE SHEET (RULE 26)6. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 135 -SUBSTITUTE SHEET (RULE 26)97. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:SUBSTITUTE SHEET (RULE 26)8. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 137 -SUBSTITUTE SHEET (RULE 26)99. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:SUBSTITUTE SHEET (RULE 26)00. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 139 -SUBSTITUTE SHEET (RULE 26)01. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 140 -SUBSTITUTE SHEET (RULE 26)102. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:SUBSTITUTE SHEET (RULE 26)03. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 142 -SUBSTITUTE SHEET (RULE 26)04. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 143 -SUBSTITUTE SHEET (RULE 26)05. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 144 -SUBSTITUTE SHEET (RULE 26)06. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 145 -SUBSTITUTE SHEET (RULE 26)07. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 146 -SUBSTITUTE SHEET (RULE 26)08. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 147 -SUBSTITUTE SHEET (RULE 26)09. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 148 -SUBSTITUTE SHEET (RULE 26)10. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 149 -SUBSTITUTE SHEET (RULE 26)11. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 150 -SUBSTITUTE SHEET (RULE 26)112. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:SUBSTITUTE SHEET (RULE 26)13. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 152 -SUBSTITUTE SHEET (RULE 26)114. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:SUBSTITUTE SHEET (RULE 26)15. A nanoparticle composition comprising an engineered DNA-binding dimer having formula:- 154 -SUBSTITUTE SHEET (RULE 26)116. A method for modifying expression of a bZIP protein target gene in a cell, the method comprising providing to the cell the nanoparticle composition of any of claims 1-115.
117. The method of claim 116, wherein the bZIP protein target gene is c-Fos.
118. The method of claim 116, wherein the bZIP protein target gene is c-Jun.
119. The method of claim 116, wherein the bZIP protein target gene is XBP1.
120. The method of claim 116, wherein the bZIP protein target gene is ATF4.
121. The method of claim 116, wherein the bZIP protein target gene is ATF6.
122. The method of claim 116, wherein the bZIP protein target gene is C / EBPp.
123. A method for introducing the engineered DNA-binding dimer of the nanoparticle composition of any of claims 1-115 into a cell, the method comprising contacting the cell with the nanoparticle composition.
124. A method for reducing an amount of a bZIP protein bound to DNA in a cell, the method comprising contacting the cell with the nanoparticle composition of any of claims 1-115 to the cell.
125. The method of claim 124, wherein the bZIP protein is c-Fos.
126. The method of claim 124, wherein the bZIP protein is c-Jun.
127. The method of claim 124, wherein the bZIP protein is XBP1.
128. The method of claim 124, wherein the bZIP protein is ATF4.
129. The method of claim 124, wherein the bZIP protein is ATF6.
130. The method of claim 124, wherein the bZIP protein is C / EBPp.
131. A method for treating a subject for a condition, the method comprising administering to the subject an effective amount of the nanoparticle composition of any of claims 1-115, wherein the condition is affected by expression of a gene under the control of a bZIP transcription factor.
132. The method of claim 131, wherein the condition is fibrosis.- 155 -SUBSTITUTE SHEET (RULE 26)133. The method of claim 132, wherein the fibrosis is liver fibrosis, renal fibrosis, cardiac fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), scleroderma, psoriasis, or myelofibrosis.
134. The method of claim 131, wherein the condition is cancer.
135. The method of claim 134, wherein the cancer is leukemia, lymphoma, myeloma, triple negative breast cancer, prostate cancer, pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinoma, ovarian cancer, lung adenocarcinoma, liver cancer, glioblastoma, renal cell carcinoma.
136. The method of claim 134, wherein the cancer is breast cancer.
137. The method of claim 136, wherein the breast cancer is triple negative breast cancer.
138. The method of any of claims 134-137, further comprising administering to the subject an additional cancer therapy.
139. The method of claim 138, wherein the additional cancer therapy is chemotherapy, radiotherapy, immunotherapy, or a proteasome inhibitor.
140. The method of any of claims 134-139, wherein the subject was previously treated with a cancer therapy.
141. The method of claim 140, wherein the subject was determined to be resistant to the cancer therapy.
142. The method of claim 140 or 141, wherein the cancer therapy comprises chemotherapy, radiotherapy, immunotherapy, or a proteasome inhibitor.
143. The method of claim 131, wherein the condition is diabetes.
144. The method of claim 143, wherein the condition is type 1 diabetes.
145. The method of claim 143, wherein the condition is type 2 diabetes.
146. A nanoparticle composition comprising an engineered peptide having the sequence: Ac-IRRERNKMAAAKSRNRRRECTDTLEDETDQLE-NH2(SEQ ID NO:59), AC-IRRERNKMAAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO: 60),- 156 -SUBSTITUTE SHEET (RULE 26)Ac-IRRERNKMAAAKSRNRRRECIDELQAEIEQLE-NBL (SEQ ID NO:61),Ac-IRRERNKM AAAKSRNRRRECIDEIQAEIEQIE-NH2 (SEQ ID NO: 62), AC-IRR#RNK#AAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO:63), Ac-IRRERNKMAAAKSRNRRRECL#ELQ#EIEQLE-NH2(SEQ ID NO: 64), AC-IRR#RNK#AAAKSRNRRRECIDELQAEIEQLE-NH2(SEQ ID NO: 65), AC-IRRERNKMAAAKSRNRRRECI#ELQ#EIEQLE-NH2(SEQ ID NO: 66), AC-IRR#RNK#AAAKSRNRRRECIDEIQAEIEQIE-NH2(SEQ ID NO: 67),AC-IRRERNKMAAAKSRNRRRECI#EIQ#EIEQIE-NH2(SEQ ID NO: 68), AC-EEKRRIRRERNKMAAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO: 69), AC-EEKRRIRR#RNK#AAAKSRNRRRECLDELQAEIEQLE-NH2 (SEQ ID NO: 70), or AC-EEKRRIRRERNKMAAAKSRNRRRECL#ELQ#EIEQLE-NH2 (SEQ ID NO:71), whereinAc is acetyl; and# is (S)-2-(4’-pentenyl)alanine.
147. The nanoparticle composition of claim 146, wherein the engineered peptide has the sequence Ac-IRRERNKMAAAKSRNRRRECI#EIQ#EIEQIE-NH2 (SEQ ID NO: 68).
148. A nanoparticle composition comprising an engineered peptide having the sequence: Ac-RK RM RNRI AASKSRKRKLERI AKmLEEKVKTLK-NEb (SEQ ID NO: 72), Ac-RKRMRNRIAASKSRKRKLERIARLKmEKVKTLK-NH2 (SEQ ID NO:73), Ac-RKRMRNRIAASKSRKRKLERAAELKmEKVATLK-NBL (SEQ ID NO: 74), Ac-RKRMRNRIAASKSRKRKLERIARLKmEKIKTLK-NBL (SEQ ID NO: 75), Ac-RKRMRNRIAASKSRKRKLERIARIKmEKIKTIK-NH2(SEQ ID NO: 76), Ac-RKR#RNR#AASKSRKRKLERIARLKmEKVKTLK-NH2 (SEQ ID NO:77),- 157 -SUBSTITUTE SHEET (RULE 26)Ac-RKRMRNRIAASKSRKRKLERI#RLKm#KVKTLK-NH2(SEQ ID NO: 78),Ac-RKR#RNR#AASKSRKRKLERIARLKmEKIKTLK-NH2 (SEQ ID NO:79),Ac-RKRMRNRIAASKSRKRKLERI#RLKm#KIKTLK-NH2 (SEQ ID NO: 80),Ac-RIKAERKRMRNRIAASKSRKRKLERIARLKmEKVKTLK-NH2 (SEQ ID NO: 81),Ac-RIKAERKR#RNR#AASKSRKRKLERIARLKmEKVKTLK-NH2 (SEQ ID NO: 82), orAc-RIKAERKRMRNRIAASKSRKRKLERI#RLKm#KVKTLK-NH2 (SEQ ID NO:83), whereinAc is acetyl;# is (S)-2-(4’-pentenyl)alanine; andKm is Lys(Mmt) or a Lys residue linked to a maleimide linker.
149. The nanoparticle composition of claim 148, wherein the engineered peptide has the sequence Ac-RKRMRNRIAASKSRKRKLERI#RLKm#KIKTLK-NH2 (SEQ ID NO:80).
150. A composition comprising (i) the nanoparticle composition of claim 146 or 147 and (ii) the nanoparticle composition of claim 138 or 139.
151. A method for generating a nanoparticle composition, the method comprising subj ecting the composition of claim 142 to conditions sufficient to form a side-by-side interpeptide linkage between the engineered peptide of the nanoparticle composition of claim 136 or 137 and the engineered peptide of the nanoparticle composition of claim 138 or 139.
152. The method of claim 151, wherein the side-by-side interpeptide linkage comprises a maleimide-thiol adduct.
153. The method of claim 152, wherein the side-by-side interpeptide linkage isSUBSTITUTE SHEET (RULE 26)154. The method of any of claims 141-143, wherein the engineered peptide of the nanoparticle composition of claim 146 or 147 and the engineered peptide of the nanoparticle composition of claim 138 or 139 each comprise two (S)-2-(4’-pentenyl)alanine residues, wherein the composition is further subjected to conditions sufficient to generate a intrapeptide stabilizing linkage between the two (S)-2-(4’-pentenyl)alanine residues.
155. A nanoparticle composition comprising an engineered peptide having the sequence:AC-RRKLKNRVAAQTARDRKKACMSELEQQVVDLE-NH2(SEQ ID NO: 84), AC-RRKLKNRVAAQTARDRKKACLSELEQQVVDLE-NH2 (SEQ ID NO:85),AC-RRKLKNRVAAQTARDRKKACL#ELE#QVVDLE-NH2 (SEQ ID NO: 86), orAC-RRK#KNR#AAQTARDRKKACLSELEQQVVDLE-NH2 (SEQ ID NO: 87), whereinAc is acetyl; and# is (S)-2-(4’-pentenyl)alanine.
156. The nanoparticle composition of claim 155, wherein the engineered peptide has the sequence Ac-RRK#KNR#AAQTARDRKKACLSELEQQVVDLE-NH2 (SEQ ID NO:87).
157. A nanoparticle composition comprising an engineered peptide having the sequence: Ac-RRKLKNRVAAQTARDRKKARMSELKmQQVVDLE-NBE (SEQ ID NO:88), Ac-RRKLKNRVAAQTARDRKKARLSELKmQQVVDLE-NBE (SEQ ID NO: 89), Ac-RRKLKNRVAAQTARDRKKARL#ELKm#QVVDLE-NH2 (SEQ ID NO: 90), or Ac-RRK#KNR#AAQTARDRKKARLSELKmQQVVDLE-NH2 (SEQ ID NO:91), whereinAc is acetyl;# is (S)-2-(4’-pentenyl)alanine; andKm is Lys(Mmt) or a Lys residue linked to a maleimide linker.- 159 -SUBSTITUTE SHEET (RULE 26)158. The nanoparticle composition of claim 157, wherein the engineered peptide has the sequence Ac-RRK#KNR#AAQTARDRKKARLSELKmQQVVDLE-NH2(SEQ ID NO:91).
159. A composition comprising (i) the nanoparticle composition of claim 155 or 156 and (ii) the nanoparticle composition of claim 147 or 148.
160. A method for generating an engineered DNA-binding dimer, the method comprising subjecting the composition of claim 151 to conditions sufficient to form a side-by-side interpeptide linkage between the engineered peptide of the nanoparticle composition of claim 145 or 146 and the nanoparticle composition of claim 147 or 148.
161. The method of claim 160, wherein the side-by-side interpeptide linkage comprises a maleimide-thiol adduct.
162. The method of claim 161, wherein the side-by-side interpeptide linkage is163. The method of any of claims 150-152, wherein the engineered peptide of the nanoparticle composition of claim 155 or 156 and the engineered peptide of the nanoparticle composition of claim 147 or 148 each comprise two (S)-2-(4’-pentenyl)alanine residues, wherein the composition is further subjected to conditions sufficient to generate a intrapeptide stabilizing linkage between the two (S)-2-(4’-pentenyl)alanine residues.
164. A nanoparticle composition comprising an engineered peptide having the sequence:Ac-KKMEQNKTAATRYRQKKRACQEALTGELKELE-NEb (SEQ ID NO: 92), Ac-KKMEQNKTAATRYRQKKRACLEALKAELKELR-NEb (SEQ ID NO:93), AC-KKMEQNKTAATRYRQKKRACL#ALK#ELKELR-NH2 (SEQ ID NO: 94), whereinAc is acetyl; and# is (S)-2-(4’-pentenyl)alanine.- 160 -SUBSTITUTE SHEET (RULE 26)165. The nanoparticle composition of claim 164, wherein the engineered peptide has the sequence Ac-KKMEQNKTAATRYRQKKRACQEALTGELKELE-NEb (SEQ ID NO:92).
166. A nanoparticle composition comprising an engineered peptide having the sequence:Ac-KKMEQNKTAATRYRQKKRAEQEALKmGELKELE-NH2 (SEQ ID NO: 95),Ac-KKMEQNKTAATRYRQKKRAELEALKmAELKELR-NH2 (SEQ ID NO: 96), orAc-KKMEQNKTAATRYRQKKRAEL#ALKm#ELKELR-NH2 (SEQ ID NO: 97), whereinAc is acetyl;# is (S)-2-(4’-pentenyl)alanine; andKm is Lys(Mmt) or a Lys residue linked to a maleimide linker.
167. The nanoparticle composition of claim 166, wherein the engineered peptide has the sequence Ac-KKMEQNKTAATRYRQKKRAEL#ALKm#ELKELR-NH2(SEQ ID NO:97).
168. A composition comprising (i) the nanoparticle composition of claim 164 or 165 and (ii) the nanoparticle composition of claim 156 or 157.
169. A method for generating a nanoparticle composition, the method comprising subjecting the composition of claim 160 to conditions sufficient to form a side-by-side interpeptide linkage between the engineered peptide of the nanoparticle composition of claim 154 or 155 and the engineered peptide of the nanoparticle composition of claim 156 or 157.
170. The method of claim 169, wherein the side-by-side interpeptide linkage comprises a maleimide-thiol adduct.
171. The method of claim 170, wherein the side-by-side interpeptide linkage isSUBSTITUTE SHEET (RULE 26)172. The method of any of claims 159-161, wherein the engineered peptide of the nanoparticle composition of claim 164 or 165 and the engineered peptide of the nanoparticle composition of claim 156 or 157 each comprise two (S)-2-(4’-pentenyl)alanine residues, wherein the composition is further subjected to conditions sufficient to generate a intrapeptide stabilizing linkage between the two (S)-2-(4’-pentenyl)alanine residues.
173. A nanoparticle composition comprising an engineered peptide having the sequence:Ac-IRRERNNIAVRKSRDKAKMCLLELQHKVLELR-NH2(SEQ ID NO: 98), orAC-IRRERNNIAVRKSRDKAKMCL#ELQ#KVLELR-NH2 (SEQ ID NO: 99), whereinAc is acetyl; and# is (S)-2-(4’-pentenyl)alanine.
174. The nanoparticle composition of claim 173, wherein the engineered peptide has the sequence Ac-IRRERNNIAVRKSRDKAKMCL#ELQ#KVLELR-NH2 (SEQ ID NO: 99).
175. A composition comprising (i) the nanoparticle composition of claim 173 or 174 and (ii) the nanoparticle composition of claim 156 or 157.
176. A method for generating a nanoparticle composition, the method comprising subjecting the composition of claim 165 to conditions sufficient to form a side-by-side interpeptide linkage between the engineered peptide of the nanoparticle composition of claim 163 or 164 and the engineered peptide of the nanoparticle composition of claim 156 or 157.
177. The method of claim 176, wherein the side-by-side interpeptide linkage comprises a maleimide-thiol adduct.
178. The method of claim 177, wherein the side-by-side interpeptide linkage is179. The method of any of claims 166-168, wherein the engineered peptide of the nanoparticle composition of claim 173 or 174 and the engineered peptide of the nanoparticle composition of claim 156 or 157 each comprise two (S)-2-(4’-pentenyl)alanine residues,- 162 -SUBSTITUTE SHEET (RULE 26)wherein the composition is further subjected to conditions sufficient to generate a intrapeptide stabilizing linkage between the two (S)-2-(4’-pentenyl)alanine residues.
180. A method of reducing expression of a HIF protein target gene in a cell, the method comprising providing to the cell a nanoparticle composition comprising an engineered DNA-binding dimer comprising:(a) a first engineered peptide comprising (i) a modified basic domain sequence of XBP1 and (ii) a modified leucine zipper domain sequence of XBP1; and,(b) a second engineered peptide linked to the first engineered peptide via a side-by- side interpeptide linkage, the second engineered peptide comprising (i) a modified basic domain sequence of XBP1 and (ii) a modified leucine zipper domain sequence of XBP1.
181. The method of claim 180, wherein the engineered DNA-binding dimer is provided in an amount effective to reduce expression of GLUT1 in the cell.
182. The method of claim 180, wherein the engineered DNA-binding dimer is provided in an amount effective to reduce expression of VEGFA in the cell.
183. The method of claim 180, wherein the engineered DNA-binding dimer is provided in an amount effective to reduce expression of PGK1 in the cell.
184. The method of any of claims 180-183, wherein the HIF protein is HIF la.
185. The method of any of claims 180-183, wherein the HIF protein is HIF2a.- 163 -SUBSTITUTE SHEET (RULE 26)86. The method of any of claims 180-183, wherein the engineered DNA-binding dimer has formula- 164 -SUBSTITUTE SHEET (RULE 26)187. The method of any of claims 180-183, wherein the engineered DNA-binding dimer has formulaSUBSTITUTE SHEET (RULE 26)188. The method of any of claims 180-183, wherein the engineered DNA-binding dimer has formulaSUBSTITUTE SHEET (RULE 26)189. The method of any of claims 180-188, wherein the cell is a cancer cell.
190. The method of any of claims 180-188, wherein the cell is a breast cancer cell.
191. The method of any of claims 180-188, wherein the breast cancer cell is a triple negative breast cancer cell.- 167 -SUBSTITUTE SHEET (RULE 26)
Citation Information
Patent Citations
Minimalist bZIP Proteins and uses thereof
US20070141672A1
Nanobody dimers linked via c-terminally engineered cysteins
US20190100599A1
Compositions and methods of modulating HIF-2a to improve muscle generation and repair
US20210169920A1
Oligonucleotide-based proteolysis targeting chimera
US20210269803A1
Compositions and methods for DNA binding and transcriptional regulation
WO2023097249A2
